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57 ABSTRACT 
Multi-phase polymeric microspheres containing a mo 
lecular compound dispersed in a polymeric matrix are 
described. Methods for preparing the multi-phase mi 
crospheres are also described, which includes a multiple 
emulsion solvent evaporation technique. Drug loading 
efficiencies between 80 to 100% were achieved using 
the described methods. Particular ratios of the W/O 
emulsion to polymer, and concentration of surfactant 
and dispersion media (mineral oil) provide highly effi 
cient multi-phase microspheres. In particular embodi 
ments, the multi-phase microspheres feature a high 
loading efficiency of water-soluble drugs, and also elim 
inates partitioning of the water soluble agent into the 
polymer acetonitrile (solvent) phase, thus preventing 
low encapsulation efficiency. The described multi 
phase microspheres possess efficient drug loading, re 
lease properties, and drug stability, and also provide a 
vehicle for long term therapeutic release of a biologi 
cally active molecule for therapeutically effective peri 
ods of time. Molecular compounds which may be incor 
porated within the multi-phase microspheres include 
both water-soluble and water-insoluble drugs, proteins 
(e.g. TNF), peptides, and chemicals. The molecular 
compound is protected within an oily droplet, and 
contact with polymer, surfactant, organic solvents, and 
other potentially denaturing agents is prevented. 
62 Claims, 16 Drawing Sheets 
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PREPARATION AND USES OF MULT-PHASE 
MCROSPHERES 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to the field of drug 
delivery systems, particularly those which involve mi 
crocapsules or microspheres. In addition, the present 
invention proposes methods for the preparation of par 
ticular multi-phase microspheres, as well as methods for 
their use in treating animals, including humans. The 
presently described microspheres also relate generally 
to the field of biodegradable in vivo delivery devices for 
proteins, peptides and other molecular compounds. 
2. Background of the Art 
The preparation and synthesis of a number of recom 
binant proteins has been the subject of a recent upsurge 
in research efforts. However, many proteins and pep 
tides have short biological half lives, and as a conse 
quence, delivery of most therapeutically valuable phar 
maceuticals requires a regimen of multiple individual 
injections for desired therapeutic efficacy in a patient. 
one way in which multiple individual injection regi 
mens have been avoided is through the use of biode 
gradable microcapsules, preferably those which are 
capable of releasing the particular biologically active 
molecule continuously and at a controlled rate. Most 
preferably and ideally, such a system would provide for 
a continuous and controlled rate of drug delivery over 
a therapeutically valuable period of time. Such methods 
for the delivery of therapeutically valuable substances, 
such as proteins, peptides and pharmacologically active 
molecules, as well as systems for their effective delivery 
in an animal, have become important areas of research. 
However, for so-me biologically active molecules, a 
therapeutically effective delivery period will require 
continuous and sustained delivery over weeks or even 
months. In this regard, encapsulated pharmaceuticals 
have achieved only limited success, with days/weeks 
being the limit of even the most protracted systems 
available. 
Present delivery systems include biodegradable mi 
crospheres and/or microcapsules which include biode 
gradable polymers, such poly d,l-lactic acid (PLA) and 
copolymers of tactic acid and glycolic acid (PLGA). 
These particular polymers are currently the most 
widely used biodegradable polymers employed in sus 









glycolic acid may be obtained by polycondensation of 50 
lactic acid or glycolic acid in the presence or in the 
absences of a catalyst or other activator. Microcapsules 
prepared from such materials may be administered in 
tramuscularly or by other parenteral routes. 
Some PLA and PLGA microspheres exist which 
contain water-soluble compounds such as quinidine 
sulfate, luteinizing hormone releasing hormone 
(LHRH) agonists.6, and less water-soluble drugs such as 
phenobarbitone. Biodegradable microspheres have 
also been reported which contain such drugs as ste 
roids, 13, anticancer agents 12.1, cardiac drugs, and 
peptides, 6.7, specifically prepared with the polymers 
polylactic acid and copolymers of lactic acid and gly 
colic acid. The biological response modifiers (BRMS) 
have also been described in association with particular 
microcapsules. 
However, the water solubility of a number of biologi 




of the most limiting factors in optimizing molecular 
compound loading efficiency in biodegradable micro 
spheres and/or microcapsules, specifically, when a con 
ventional oil/water emulsion system is used in the sol 
vent evaporation process. In this regard, it has been 
observed that the loading efficiency of water-soluble 
drugs into, for example, PLA or PLGA-polymeric 
microspheres is relatively low when conventional oil/- 
water systems are used in a solvent evaporation pro 
cess 131. This has been attributed to the observation that 
such drugs readily diffuse into the aqueous outer phase 
of the emulsion system. 
Some of the inventors' prior work addresses the low 
efficiency of drug loading due to solubility problems by 
adjusting the pH of the aqueous phase in the microen 
capsulation procedure. Adjusting the pH of the aqueous 
phase was shown to maximize loading efficiency of the 
particular water-soluble molecule, quinidine sulfate, in 
PLA microspheres, using a conventional O/W emul 
sion system in the solvent evaporation process. One of 
the inventors had found that by increasing the pH of the 
water soluble molecular compound solution, the solu 
bility of the water soluble molecular compound will 
increase in the solution. Thus, the water soluble molecu 
lar compound is prevented/inhibited from diffusing 
from the microcapsule into the external aqueous phase. 
Anhydrous emulsion systems have also been de 
scribed in the preparation of microcapsules. For exam 
ple, a phenobarbitone microencapsulation system was 
developed by Jalil and Nixon (1989)18 using poly(1-lac 
tic acid). Acetonitrile was used as the solvent ("W'- 
phase) for the poly(1-lactic acid) and the drug, and light 
mineral oil was used as the continuous dispersion me 
dium (O-phase). However, in these microspheres, drug 
particles were dispersed in direct contact with the poly 
mer matrix (conventional "matrix-type' system). 
Direct contact of drug particles with a polymer ma 
trix has been observed to contribute to degradation of a 
protein, perhaps by monomer and diner residues pres 
ent in the polymer (inventors' unpublished observa 
tions). Polymeric degradation would also result in such 
"matrix' systems upon incorporation of proteins or 
enzymes in such a system, as direct contact with the 
polymer is again not prevented. 
Most of the microspheres described in the literature 
belong to the class of "matrix-type" drug delivery cap 
sules, in which the "foreign' (i.e. drug) particles are 
dispersed homogeneously in direct contact with the 
polymer. These processes also frequently involve direct 
contact between the drug and a polymer solvent, such 
as acetonitrile or methylene chloride. In these systems, 
direct contact between the particular biologically ac 
tive molecule and the polymer, the polymer solvent or 
with enzymes in the biological system promote degra 
dation of the intended pharmaceutical. Specifically, 
previous workers have shown that the monomer and 
dimer residues in the polymer may degrade the protein, 
and other workers have shown that proteins 32 and 
enzymes in direct contact with the polymer will result 
in polymeric degradation over time. 
In order to avoid interactions of sensitive substances 
(i.e., protein/peptides) with particular polymers, such 
as PLA and PLGA, in a delivery system, multiple 
walled microcapsular devices employing conventional 
multiple emulsion techniques were proposed. For exam 
ple, emulsion techniques have been reported using poly 
mers to form microspheres having a multiple walled 
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structure. For example, albumin containing-biodegrada 
ble microspheres have been reported by Saha et al.25 
using an O/W/O multiple emulsion solvent evaporation 
technique. In addition, Morris et al.2described a three 
ply walled microsphere composed of acacia/ethylcel 
lulose/acacia layers prepared by using a W/O/W multi 
ple emulsion solvent evaporation technique. However, 
drug loading capacities of these devices are limited in 
that sufficient amounts of the polymer must be present 
to facilitate formation of a stable microsphere. While 
the use of highly potent drugs may circumvent the 
drug-loading capacity problem, sufficiently "con 
trolled' biodegradable systems for providing a constant 
and controlled drug release to justify the high cost of 
potent drug proteins and peptides are not currently 
available. 
Despite the advantages to be gained from a multi 
walled microsphere delivery device, the systems thus 
far described are limited to relatively low levels of drug 
loading capacity, since sufficient polymer must be pres 
ent in order to form a sufficiently stable -microsphere. 
Carefully controlled drug release and high efficiency in 
drug loading (preferably more than 90%) are required 
features in clinically efficacious microencapsulation 
techniques, particularly in light of the high potency and 
in many cases, prohibitive costs of synthetic peptide/- 
protein drugs. 
Drug loading capacity loading efficiency, stability 
and controlled releases have been observed as limiting 
factors even when highly potent water soluble drugs 
are incorporated into microparticles. Thus, difficulties 
relating to the accomplishment of carefully controlled 
and sufficiently extended drug release rates remain. In 
addition, potential drug degradation from direct contact 
of the particular biologically active molecule and the 
polymer as well as from contact of the polymer with 
enzymes in vivo, potentially remain. 
Present techniques used by biotechnology and phar 
maceutical companies to encapsulate peptides in biode 
gradable polymers utilize a solvent-nonsolvent system 
which unfortunately suffers from the disadvantage of 
high solvent residuals, poor content uniformity of the 
peptide in the microspheres, and instability due to the 
contact of the biological agent with the polymer, or 
ganic solvent (e.g. methylene chloride, acetonitrile), 
and some cases, a surfactant. 
Thus, while some biotechnology companies in the 
United States, Japan and Europe have achieved some 
measure of success in developing potent peptides and 
proteins for a variety of clinical conditions, major chal 
lenges remain to be solved by pharmaceutical scientists 
in developing stable and optimized control-release for 
mulations for potent water soluble bioactive agents. 
Thus, a microcapsule delivery system which permitted 
the efficient loading of water-soluble biologically active 
molecules in a biodegradable carrier system would pro 
vide a medically significant advance in the clinically 
- valuable and cost-effective preparations for long-term 
in vivo drug delivery of potent water-soluble chemicals, 
proteins and peptides. 
SUMMARY OF THE INVENTION 
The present invention provides a unique multi-phase 
microsphere system having a high drug loading effi 
ciency, and, methods for preparing same, which feature 
a drug/protein contained within a fixed oil to efficiently 
incorporate virtually any molecular compound. The 













which contain a water-soluble molecular compound, 
for example, is generally described for purposes of the 
present invention as a multiple emulsion solvent evapo 
ration technique. In a most preferred aspect of the pres 
ent invention, a multi-phase microsphere system for the 
efficient incorporation of a water soluble molecular 
compound is provided. Molecular compounds which 
are not water soluble may also be employed in the pres 
ently described multi-phase microspheres. Such molec 
ular compounds may be prepared together in a fixed oil 
directly, with the resulting mixture then being added to 
a polymer and solvent solution and a "dispersion' oil 
medium, so as to provide multi-phase microsphere. 
Molecular compounds which are not stable in an 
aqueous solution may also be employed with the de 
scribed multi-phase microspheres. For molecular com 
pounds which are not particularly stable in water (e.g., 
subject to denaturation), the multi-phase microspheres 
of the present invention may be prepared by drying the 
final microspheres under a vacuum to remove any 
water which may be present in the microemulsion of the 
multi-phase microsphere. 
For molecular compounds which may become unsta 
ble from dehydration, and where the stability of the 
molecular compound is sensitive to water, the described 
delivery system may be provided by suspending an 
amount of the molecular compound directly in a fixed 
oil, such as soybean oil, which may then be combined 
with a polymer and polymer solvent solution in a "dis 
persion' medium, such as mineral oil (where the poly 
mer solvent is acetonitrile 
In all of the delivery systems described, the molecular 
compound is protected against continued denaturation 
from any included water. Alternatively, the microemul 
sion of the multi-phase microspheres of the present 
invention, containing a molecular compound which is 
unstable in water, may be prepared by first lyophilizing 
a preparation of the molecular compound in water and 
oil. The lyophilization will act to remove or decrease 
the water content of the preparation, thus preserving 
the stability of the molecular compound. The lyophi 
lized form of the preparation thus takes on a powder 
form which may then be emulsified in a solution of a 
polymer and polymer solvent in a "dispersion' oil me 
dium. 
For purposes of describing the subject matter of the 
present invention, the term, "multi-phase' relates to a 
modified matrix type microsphere wherein the molecu 
lar compound is not in direct contact with the polymer 
, while the term "conventional' relates to a matrix type 
of microsphere structure wherein the drug is dissolved 
or dispersed throughout the polymer matrix the drug 
being in direct contact with the polymer. 
An "emulsion' for purposes of describing the present 
invention is a stable dispersion of one liquid in a second 
immiscible liquid.29An example of such would be milk. 
An "immiscible" liquid is a liquid which is not soluble in 
another substance or liquid, for example, oil in water.30 
In contrast, two substances that are mutually soluble in 
all proportions are is. said to be miscible.30 
In one particularly preferred aspect of the present 
invention, a microemulsion of a fixed oil and an aqueous 
solution of a water-soluble molecular compound, such 
as a protein, peptide or other water-soluble chemical if 
prepared. This emulsion is of the "water-in-oil" type 
(oil as the continuous phase) as opposed to an "oil-in 
water" system (water as the continuous phase). The 
term "continuous phase' as used in the description of 
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the present invention is the external phase, as compared 
to the "dispersed phase", which is the internal phase. 
The protein, peptide, chemical or other drug either 
after lyophilization of the molecular compound in a 
fixed oil mixture (in the case of a protein, peptide or 
drug denatured in the presence of water) or as a micro 
emulsion prepared from the molecular compound in an 
aqueous phase in water (in the case of a protein, peptide 
or drug which is not denatured in the presence of wa 
ter), is incorporated as part of the multi-phase micro 
sphere of the present invention. The "external' oil 
phase of the microsphere includes an oil, such as min 
eral oil, which is incompatible with the particular sol 
vent of a polymer-insolvent preparation. 
As the molecular compound of the present invention 
is effectively "trapped' within multiple tiny oil droplet 
reservoirs throughout the polymer matrix, the incorpo 
rated molecular compound does not partition into the 
polymer-insolvent outer phase during formulation, or 
into the polymer matrix of the hardened solvent evapo 
rated multi-phase microsphere. Aluminum monostea 
rate also helps to increase the viscosity of the fixed oil in 
which the molecular compound is effectively held, thus 
further preventing the molecular compound from dif 
fusing out of the microsphere. 
A multiple emulsion technique with organic solvents 
to form microcapsules has been described generally in 
the past. However, none of the prior reported systems 
describe or suggest either a system wherein a water 
insoluble molecular compound in a fixed oil, or a micro 
emulsion of an aqueous solution of a water soluble pro 
tein or drug in a fixed oil, is prepared and subsequently 
formulated in combination with a polymer-insolvent 
solution and dispersion (oil) medium. The present in 
ventors describe for the first time molecular compound 
in-oil preparation (mixture or microemulsion) as part of 
a multi-phase microsphere system. This unique design 
prevents contact of the molecular compound with po 
tentially degrading substances, such as the polymer. 
The novel approach of lyophilizing a microemulsion of 
a particular water-denatured or unstable molecular 
compound and water in a fixed oil and mixing the ly 
ophilized product with a solution of polymer and sol 
vent in a dispersion oil broadens the applicability of the 
present invention for use with virtually any compound. 
The basic technological breakthrough provided with 
the present disclosure may be applied in preparing slow 
release, long-acting, multi-phase microspheres with 
virtually any micro- or macromolecule, including syn 
thetic, potent proteins and peptides. Thus, the proposed 
compositions and methods present a highly cost effec 
tive and therapeutically valuable delivery system. 
In one particular embodiment of the present inven 
tion, a delivery system for a molecular compound com 
prising a multi-phase microsphere which includes a 
molecular compound contained within a fixed oil as 
part of a polymeric matrix is provided. The tern "mo 
lecular compound' as used in the description of the 
present invention includes peptides, proteins as well as 
other biocompatible and/or potentially bioactive/phar 
macologically active molecules. Potentially useful mo 
lecular compounds which may be formulated in the 
disclosed multi-phase microspheres of the present in 
vention include a variety of compounds known as 
"drugs" and other biocompatible macro- and mi 
cromolecules. 
Those compounds which are substantially or only 













tion with the disclosed multi-phase microsphere system 
upon enhancing the water solubility of the particular 
compound through adjustment of pH of the agent/com 
pound in a water solution etc. before preparation of the 
aqueous solution of the water soluble agent/compound 
in oil to form a "microemulsion'. Alternatively, molec 
ular compounds which are unstable or exhibit minimal 
stability due to dehydration or denaturation upon expo 
sure to water may be formulated as described with an 
additional step being included wherein the final multi 
phase microspheres are dried under vacuum to remove 
any water from the microspheres. A second option of 
preparing a water/oil microemulsion of the drug and 
oil, as already described, with the microemulsion being 
lyophilized to remove or decrease the water content 
exists to preserve stability. Such a system would result 
in finely dispersed particles in the oil phase prior to the 
encapsulation process. The lyophilized powder which 
results may then be emulsified in a polymer and solvent 
and a dispersion oil medium. 
By way of example, molecular compounds which 
may be used in conjunction with the present invention 
included tumor-necrosis factor (TNF-a and 6), chlor 
pheniramine maleate (CPM), diphenhydramine hydro 
chloride (DPH), promazine hydrochloride (PMZ), and 
procainamide hydrochloride (PRC). Other pharmaco 
logically active substances which may be prepared as a 
"microemulsion' of the present system, upon slight 
adjustment of pH, include the interferons (IFN-a, 6, y) 
macrophage activating factor (MAF), the interleukins 
(IL-1,2,3,4,5,6), colony stimulating factor (CSF), tumor 
degenerating factor (TDF), epidermal growth factor 
(EGF), erythropoietin (EPO), tissue plasminogen acti 
vator (TPA), insulin, urokinase, luteinizing hormone 
releasing hormone (LHRH), monoclonal antibodies, 
superoxide dismutase (SOD), the P-450 enzymes, bo 
vine serum albumin (BSA), and oxytocin. Other water 
soluble molecular compounds which may be used in 
conjunction with the described method for preparing 
multi-phase microspheres include the steroids and atri 
opeptin III. 
Most preferably, those water-soluble molecular com 
pounds most preferred for use in the presently disclosed 
multi-phase microspheres are chlorpheniramine maleate 
(CPM), diphenhydramine hydrochloride (DPH), pro 
cainamide hydrochloride, promazine hydrochloride 
(PMZ), or brilliant blue. 
Most preferably, the multi-phase microspheres of the 
present invention are about 150 microns (u) in size. 
Even more preferably, the microspheres are between 
50p and 100 in size. However, the microspheres of the 
present invention may be formulated to achieve virtu 
ally any size less than 150 by adjustment of agitation 
rates, viscosity of the emulsion (i.e., lowering the vis 
cosity of the oil), increasing the temperature used dur 
ing formulation etc., sufficient to decrease particle size 
and prevent separation of the "microemulsion' particles 
from the polymer-insolvent mixture during formulation. 
The multi-phase microspheres of the present inven 
tion further include a polymeric substance. The poly 
mers poly (d,l-lactic acid) and poly (d,l-lactic) co 
glycolic tactic acid are included as among the most 
preferred polymers to be used in conjunction with the 
presently disclosed multi-phase microspheres. How 
ever, virtually any biodegradable and biocompatible 
polymer may be used in the preparation of the present 
invention. The biocompatible polymer must be soluble 
in a solvent which is immiscible with the dispersion 
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medium of choice (for example, the dispersion medium 
mineral oil). 
The microemulsions (i.e., drug/protein solution-in-oil 
emulsion) described as part of the inventive multi-phase 
microspheres may be prepared with any variety offixed 
oils. By way of example, such fixed oils include saf 
flower, soybean, peanut, cotton seed, sesame, or cod 
liver oil. Soybean, sesame, and safflower oil are most 
preferred in the preparation of the described "micro 
emulsion'. Oils used clinically in intravenous fat emul 
sions include the soybean and safflower oils. 
Mineral oil is most preferably used as part of the 
"dispersion' medium in the invention. The microemul 
sion, lyophilized molecular compound product or anhy 
drous molecular compound in fixed oil preparation is 
combined with a polymer/solvent in such a mineral oil 
dispersion medium to form the multiple emulsion of the 
invention. However, any oil may be used in the "disper 
sion' medium which is incompatible with the particular 
solvent used to dissolve the polymer. 
The present inventors have found that, provided the 
protein is stable in water, the formation of a microemul 
sion of the aqueous water-soluble protein molecular 
compound solution in oil, will stabilize the protein by 
preventing contact of the protein molecule directly 
with the polymer, the organic solvents, if any used, and 
any surfactants used to prepare the microspheres. Thus, 
the delivery system of the present invention includes an 
aqueous molecular compound solution-in-oil emulsion 
of the water soluble molecular compound which com 
prises numerous tiny oily reservoirs within the polymer 
matrix of the multi-phase microsphere. The water-solu 
ble molecular compound thereby remains essentially 
isolated from all potentially degrading substances. 
The multi-phase microspheres of the delivery system 
comprise water soluble molecular compounds such as 
water-soluble proteins, peptides or drugs. Most prefera 
bly, the water-soluble molecular compound of the de 
scribed delivery system includes CPM. In a most partic 
ularly preferred embodiment of the described delivery 
system, the molecular compound tumor-necrosis factor 
in water is prepared in the fixed oil, soybean oil, and the 
mixture lyophilized to a powder. The microemulsion of 
TNF in water with oil is lyophilized to remove essen 
tially all of the water before dispersion of the micro 
emulsion in the polymer solution (polymer plus poly 
mer solvent), the mixture of which is then combined in 
a "dispersion' oil. 
The present disclosure demonstrates a number of 
important differences between the present inventive 
multi-phase microspheres and other microsphere and 
microcapsule systems. Specifically, while particular 
polymer degradation rates between the two types of 
microspheres (i.e., multi-phase V. conventional) were 
almost the same, the drug dissolution rate from the 
microsphere in each of the systems was significantly 
different. Specifically, the molecular compound dissolu 
tion rates of the conventional microspheres were dem 
onstrated to increase as the overall drug content of the 
microsphere was increased. In contrast, the multi-phase 
microspheres disclosed herein were demonstrated to 
release the particular compounds incorporated therein 
at a rate independent of the particular molecular com 
pound content of the microsphere. 
This important observation highlights one particular 
advantage of the present systems over those proposed in 
the literature, in that a constant and fixed rate of deliv 









ficing high drug loading efficiency in the microsphere. 
Other systems must be modified in order to achieve any 
particular rate of drug delivery, and currently do not 
provide for extended and slow drug release over thera 
peutically useful periods of time. The constant and slow 
rate of drug delivery may be attributable to the design 
of the multi-phase microspheres, which require that the 
molecular compound first traverse the water-oil barrier, 
and the polymer barrier of the polymer matrix, before 
the molecular compound/drug may diffuse out of the 
microsphere into the surrounding media or system (e.g., 
the system of an animal). Highly controlled and con 
stant drug release is accomplished, along with the added 
advantage of greater than 80% drug loading efficiencies 
of these agents. 
Another aspect of the present invention includes a 
method for providing sustained release of a molecular 
compound (most preferably, water soluble molecular 
compounds) in an animal. One particularly preferred 
embodiment of this method comprises preparing a for 
mulation comprising polymeric multi-phase micro 
spheres containing a microemulsion of the water soluble 
molecular compound in a fixed oil and administering an 
amount of the formulation effective to provide sus 
tained release of the water-soluble molecular compound 
in the animal for a prescribed period of time. 
More particularly, the multi-phase microspheres of 
the defined method for use in an animal comprise a 
biodegradable polymer such as PLA or PLGA. The 
method employs multi-phase microspheres which in 
clude any variety of molecular compounds, such as 
proteins, chemicals, peptides or other pharmacologi 
cally active non-toxic drugs. 
In a most preferred aspect of the invention, the 
method includes a water-soluble molecular compound 
which is active as a therapeutic agent. A microemulsion 
of an aqueous solution of the water soluble molecular 
compound in a fixed oil is prepared and then mixed with 
a polymer solution and dispersion oil medium. No di 
rect contact of organic solvent and the water soluble 
molecular compound therefor occurs. 
Potentially therapeutic molecular compounds which 
are not stable in water may also be incorporated in the 
multi-phase microspheres in a method to provide sus 
tained release of the agent in an animal. These types 




may be prepared as already described (e.g., lyophiliza 
tion mixture of molecular compound in a fixed oil pre 
pared with polymer, solvent and dispersion oil directly, 
standard preparation with extended drying or hardened 
microspheres to remove water). 
As part of the described method, the particular for 
mulation may be administered intramuscularly or by 
other parenteral routes. Most preferably, the formula 
tion is administered intramuscularly. It is proposed that 
delivery of the molecular compound may be achieved 
for an average of three months in vivo with the de 
scribed multi-phase microspheres. However, depending 
on the particular polymer used, the particular molecular 
compound used, etc., the multi-phase microspheres may 
be formulated to provide delivery in vivo of the agent 
for up to 1 year. 
In still another embodiment of the present invention, 
a method for preparing multi-phase microspheres is 
provided. Most preferably, the claimed method for 
preparing multi-phase microspheres containing a mo 
lecular compound comprises preparing a solution of the 
molecular compound (in water) with a fixed oil to form 
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a microemulsion, mixing a biocompatible polymer and a 
polymer solvent together to form a polymer solution, 
dispersing the microemulsion into the polymer solution 
to form a W/O/"O" emulsion, mixing the W/O/"O" 
emulsion together in a dispersion oil which is incompat 
ible with the polymer solvent to form a multiple emul 
sion, agitating and removing the solvent from the multi 
ple emulsion to form hardened microspheres and wash 
ing and drying the hardened microspheres to form mul 
ti-phase microspheres containing the molecular com 
pound. So prepared, the described -multi-phase micro 
spheres are suitable for use as a long acting drug deliv 
ery device for virtually any protein, peptide, chemical 
or therapeutic agent. Where the particular molecular 
compound is unstable in water, the microemulsion may 
first be lyophilized to remove water and enhance the 
stability of the molecular compound before mixture 
with the polymer, polymer solvent and "dispersion' 
(oil) medium. 
Most preferably, the invention provides a method for 
preparing a multi-phase microsphere containing water 
soluble molecular compounds. In this embodiment, an 
aqueous solution of the water soluble molecular com 
pound is prepared. Where the molecular compound is 
stable in water, no lyophilization of the microemulsion 
is required before mixing same in a solution of polymer 
and solvent in a "dispersion' (oil) medium. 
Most preferably, the particular fixed oil of the micro 
emulsion is soybean, safflower, cottonseed, peanut, ses 
ame or cod liver oil. In addition, the microspheres may 
be most efficaciously prepared with the polymer sol 
vent, acetonitrile. Again, the particular biodegradable 
polymer preferred for use in the preparation of the 
described microspheres is PLA or PLGA. Mineral oil 
would be used as a suitable oil of the "dispersion' me 
dium where the polymer solvent is acetonitrile. Thus, 
the particular polymer-solvent mixture in a most partic 
ularly preferred embodiment of the claimed method is a 
PLA or PLGA/acetonitrile solution. 
As part of the claimed method, the solvent is re 
moved from the W/O/"O" emulsion by the process of 
evaporation under atmospheric pressure, wherein the 
microemulsion is subject to constant agitation (i.e., stir 
ring) in the dispersion (i.e., mineral oil) medium. The 
multi-phase microspheres produced according to the 
described method are most preferably about 150 mi 
crons (pl) in size. Even more preferably, the multi-phase 
microspheres are to be prepared so as to be between 









crospheres may be prepared so as to attain a size of 50 
between about 50 microns and about 100 microns by 
slight modification of the speed or agitation and of the 
viscosity of the microemulsion/polymer solution sys 
tem, employing other surfactants, modifying the dilu 
tions of polymer solution employed, and/or increasing 
the temperature employed during formulation. 
In certain preferred embodiments of the described 
method, the water-soluble molecular compound is a 
water-soluble protein, peptide, chemical, dye or drug. 
Examples include brilliant blue, CPM, DPH, PMZ or 
PRC. Even more preferably, the aqueous phase de 
scribed in conjunction with the preparation of the multi 
phase microspheres includes Tween 80 at about 4% 
W/W, (or about 1% W/W of the microemulsion). In 
addition, the oil phase as described in the present meth 
ods most preferably includes Span 80, at a concentra 





In an even more particularly preferred embodiment 
of the method for preparing multi-phase microspheres 
containing a water-soluble molecular compound, the 
method comprises, preparing a first mixture of a water 
soluble molecular compound in water, gelatin and 
Tween 80 to form an aqueous phase, preparing a second 
mixture of an amount of aluminum stearate (particu 
larly, aluminum monostearate) and a volume of a fixed 
oil to provide a 2% aluminum stearate and about 5% 
(4% in the W/O emulsion) W/W of Span 80 oil phase, 
combining the first mixture with the second mixture to 
form a coarse W/O emulsion, processing the coarse 
W/O emulsion into a fine W/O microemulsion, prepar 
ing a third mixture of a biodegradable polymer and a 
polymer solvent, combining a quantity of the fine W/O 
microemulsion with the third mixture to form a 
W/O/"O" emulsion, preparing a fourth mixture of an 
oil incompatible A, with the polymer solvent and an 
amount of Span 80, pouring the W/O/"O" into the 
fourth mixture to form a multiple emulsion, agitating 
and evaporating the solvent from the multiple emulsion 
to form hardened microspheres, separating the hard 
ened microspheres from the mixture, and washing and 
drying the hardened microspheres to form multi-phase 
microspheres containing a water-soluble molecular 
compound. Most preferably, coarse W/O emulsion is 
processed to form a fine w/o emulsion by homogeniz 
ing the coarse W/O emulsion. 
In a particularly preferred embodiment of the 
claimed method, the third mixture comprises less than 
35% W/W of the biodegradable polymer. Even more 
particularly, the method includes a third mixture which 
comprises about 33% W/W of a PLA biodegradable 
polymer in an acetonitrile polymer solvent. Where the 
biodegradable polymer is PLGA, the third mixture 
comprises about 31% W/W of PLGA in an acetonitrile 
solvent. These particular most preferred amounts of 
biodegradable polymers in a solvent of the third mixture 
has been found to optimize the loading efficiency of 
water-soluble molecules in the multi-phase micro 
spheres of the present invention. For example, loading 
efficiencies of between 80%-100% were obtained using 
this system and these relative amounts of polymer. Ex 
amples of those water-soluble molecules which may be 
included within the multi-phase microspheres of the 
present invention are the water-soluble dye brilliant 
blue and the drugs CPM, DPH, PMZ, and PRC. 
The particular emulsion-to-polymer ratio, as well as 
the concentration of surfactant to be included in the 
evaporation (i.e., same as the "dispersion' medium) 
medium (mineral oil), were parameters which the in 
ventors found to affect drug loading efficiencies in each 
of the preparations. Thus, ratios of these particular 
components in the microspheres and in the methods for 
their preparation are important to maximizing drug 
loading efficiency. 
The amount of the W/O emulsion dispersion inside 
the microspheres has also been observed by the present 
inventors to affect the loading efficiency of a particular 
biologically active agent into the microsphere prepara 
tion. Thus, the inventors have defined most preferred 
ranges of the quantity of the W/O emulsion which is to 
be included within those W/O/"O' emulsions in the 
current process. Thus, in a most particularly preferred 
embodiment of the claimed process, the quantity of the 
fine W/O emulsion (microemulsion) is to be between 
about 0.25 to 1.0 grams by weight per 1 gram of the 
polymer contained in the W/O/"O" emulsion. 
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The inventors have also observed that the loading 
efficiency of a water-soluble molecular compound into 
the described multi-phase microspheres is also affected 
by the percentage (W/W) of Span 80 included within 
the fourth mixture which includes a fixed oil and an 5 
amount of Span 80. The best drug loading efficiencies 
were observed when the fourth mixture (multiple emul 
sion) included between about 0.25% to about 2% W/W 
Span 80. Even more preferable, about 0.25% to 0.5% 
W/W of Span 80 is to be included within the fourth 10 
mixture. Finally, the most preferred concentration of 
Span 80 to be included within the fourth mixture with a 
fixed oil is about 0.25% WAW. 
While the duration of action of the multi-phase mi 
crospheres (i.e., the “in vivo life span") will depend on 
the properties of the particular biocompatible polymer 
selected and the rate of biogradation characteristic of 
the polymer, as well as the stability of the particular 
water soluble molecular compound incorporated, mi 
crospheres prepared according to the presently de 
scribed system are expected to provide a steady and 
constant release of a compound for about three months 
at a time. 
Where TNF is the molecular compound incorpo 
rated, controlled and constant drug release may be 
achieved for about 1 month. This time period will de 
pend upon the molecular weight of the polymer used, 
the site of administration of the multi-phase micro 
spheres, the polymer/drug ratio, the type and rate of 30 
degradation of the polymer (PLAYPLGA) used, the 
particle size of the "microemulsion,” and other factors 
known to those in the art. It is hypothesized that the 
described multi-phase microspheres may be so formu 
lated so as to highly controlled molecular compound 35 
release for up to 1 year in vivo. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Preparative method for multi-phase micro 
spheres containing water-soluble drugs by a multiple 40 
emulsion solvent evaporation technique. 
FIG. 2. In vitro dissolution of brilliant blue from 
multi-phase and (A) and conventional and (B) multi 
phase PLGA microspheres containing various amount 
of the dye. The medium was pH 7.4 phosphate buffered 45 
saline, 37 C. 
FIG. 2-B demonstrates a typical relatively long lag 
phase, with virtually no release of brilliant blue for 18 
days, followed by a "burst' phase of rapid release after 
20 days. The percentage of brilliant blue release in- 50 
creases with the increasing concentration of the brilliant 
blue in the microsphere (e.g., at 30 days: 40% dissolved 
brilliant blue release in the 0.2 mg/g brilliant blue mi 
crospheres; about 80% dissolved brilliant blue release in 
the 1.3 mg/g brilliant blue microspheres; about 90% 55 
dissolved brilliant blue release in the 2.5 mg/g brilliant 
blue microspheres). 
In FIG. 2-B, the dissolution profile is essentially de 
void of a lag phase. About 10% brilliant blue is released 
after about 3 days from microspheres containing 0.3 60 
mg/g, 0.4 mg/g, 0.8 mg/g or 1.0 mg/g. The percentage 
of brilliant blue release is demonstrated to be relatively 
independent of the concentration of brilliant blue in the 
microsphere. 
FIG. 3. In vitro dissolution of CPM from conven- 65 
tional and (A) and multi-phase (B) PLGA microspheres 
containing various amount of the CPM. The medium 




FIG. 4. Micrographs of a cross-section (A) and an 
outward appearance (B) of PLGA conventional micro 
spheres containing brilliant blue after an in vitro dissolu 
tion test for a week. 
FIG. 5. PLGA multi-phase microspheres with bril 
liant blue after 1 week in vivo dissolution. Cross section 
= A, outward appearance = B. 
FIG. 6. Morphological changes of conventional 
PLGA microspheres containing brilliant blue during an 
in vitro dissolution test. The samples (initial (A)) were 
observed after a week (B), 2 weeks (C) and 4 weeks (D) 
by scanning electron microscopy. 
FIG. 7. Morphological changes of multi-phase 
PLGA microspheres containing brilliant blue during an 
in vitro dissolution test. The samples (initial (A)) were 
observed after a week (B), 2 weeks (C) and 4 weeks (D) 
by scanning electron microscopy. 
FIG. 8. Photographs taken under transmitted light of 
multi-phase PLGA microspheres containing brilliant 
blue prepared by a multiple emulsion solvent evapora 
tion technique (A) and conventional PLGA micro 
spheres containing brilliant blue prepared by a W/O 
emulsion solvent evaporation technique (B). 
FIG. 9. Scanning electron micrographs of outward 
appearance of conventional (A) and multi-phase (B) 
microspheres observed after in vitro dissolution tests for 
2 weeks. 
FIG. 10. PLGA molecular weight changes of resid 
ual beads of multi-phase and conventional microspheres 
containing brilliant blue (A) and CPM (B) during in 
vitro dissolution test. The molecular weights were de 
termined by gel permeation chromatography. 
FIG. 11. Schematic features of a multi-phase micro 
sphere (A) prepared by a multiple emulsion solvent 
evaporation technique and a microsphere (B) prepared 
by a conventional solvent evaporation technique. 
FIG. 12. Drug loading efficiency of multi-phase 
PLGA microspheres as a function of the level of W/O 
emulsion dispersed in 1 gram of the polymer. 
FIG. 13. Influence of the level of Span 80 in mineral 
oil ("dispersion medium') on the drug loading effi 
ciency of multi-phase PLGA microspheres. 
FIG. 14. Comparison of drug loading efficiency be 
tween multi-phase and conventional PLGA micro 
spheres. Theoretical drug content is shown beside each 
profile. 
FIG. 15. Scanning electron micrographs of conven 
tional PLGA microspheres containing brilliant blue 
prepared by a "W"/O emulsion solvent evaporation 
technique, showing entire particles (A) and cross-sec 
tions (B). 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
Novel multi-phase microspheres containing a molec 
ular compound solution-in-oil microemulsion comprise 
the highly stable and slow releasing multi-phase micro 
spheres of the present invention. The unique water-in 
oil microemulsions are employed by the inventors in a 
multiple emulsion technique in the preparation a hybrid 
microsphere, defined as multi-phase microspheres. 
These multi-phase microspheres include numerous, tiny 
microemulsions in the form of oily droplets dispersed 
throughout a biodegradable polymer matrix. This tech 
nique innovatively provides for the elimination of 
contact between the polymer and the molecular com 
pound, as well as enhancing the slow release character 
istic of the compound from the microsphere. 
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The elegant design of the compositions (i.e. multi 
phase microspheres) and methods employing the com 
positions disclosed herein circumvent technical prob 
lens associated with microspheres and microcapsules 
described in the art, as well as those technical difficul 
ties associated with providing efficient incorporation of 
a water soluble component in a drug delivery system. 
For example, the slow release action of the presently 
disclosed multi-phase microspheres make possible the 
design of in vivo treatment regimens which are effec 
tive over therapeutically valuable and/or necessary 
treatment periods. The present methods also eliminate 
the necessity of multiple injections and/or administra 
tion of the particular pharmaceutical. In addition, the 
unique "microemulsion' design included in the claimed 
multi-phase microspheres provides for high water solu 
ble molecule loading efficiency without loss of slow and 
constant control of drug release, as compared to the 
content-dependent rate of drug delivery observed in 
conventional microsphere systems. 
The methods of the present invention provide for a 
uniquely modified multiple emulsion system as part of 
the solvent evaporation step in multi-phase microsphere 
preparation. Specifically, conventional "O"/O 
(acetonitrile-in-mineral oil) emulsions of polymer aceto 
nitrile solution and molecular compounds directly is 
replaced by a multiple emulsion system wherein the 
molecular compound is first separately emulsified with 
a fixed oil, which is then combined with a polymer-in 
solvent combination in the presence of a dispersion 
medium of an oil incompatible with the polymer sol 
vent. Thus, during the solvent evaporation process, the 
molecular compound is prevented from diffusing into 
an outer phase of the emulsion system. 
Multiple emulsion systems with organic solvents 
have been described with some limited degree of suc 
cess.21 However, because a "microemulsion" of an 
aqueous solution of the drug in an oil, or of a drug in an 
oil (in the case of water-insoluble molecular com 
pounds) is not employed as part of the preparation, the 
protein or enzyme is left in direct contact with the poly 
meric materials employed. Thus, the molecular com 
pounds of such systems would be subject to denatura 
tion/degradation through polymer contact, contact 
with a surfactant, organic solvent residuals and contact 
with organic solvents (e.g. acetonitrile). The potential 
for this type of degradation is eliminated through use of 
the disclosed methods, thus making microsphere deliv 
ery of potent and costly synthetic proteins and peptides 
a commercially feasible option. 
The presently described compositions and methods 
may be used with both water soluble molecular com 
pounds and molecular compounds which are unstable in 
aqueous solutions. Denaturation of molecular com 
pounds which are unstable in water may be prevented 
by either first lyophilizing the microemulsion of the 
aqueous solution of the molecular compound in oil 
before the "dispersion' thereof in a solution of polymer 
and solvent and a dispersion oil, or by simply drying the 
final microspheres under a vacuum to remove water 
from the microspheres. Alternatively, the drug may 
first be dispersed within a fixed oil containing aluminum 
monostearate, and the drug-oil mixture combined with 
a polymer plus polymer solvent solution and a "disper 
sion' oil. 
Poly(d,l-lactic-co-glycolic acid)(MW 57,000 lactide/- 
glycolide = 50/50) was purchased from Birmingham 










acetonitrile was purchased from Fisher Scientific Co. 
(Fairlawn, N.J.). Brilliant blue FCF was obtained from 
Allied Chemical Co. (New York, N.Y.). Soybean oil, 
light mineral oil (USP) and aluminum monostearate 
(USP/NF) were purchased from Spectrum Chemical 
Mfg. Co. (Gardena, Calif.). Sorbitan monooleate 
(SPAN 80) and polyoxyethylene sorbitan monooleate 
(Tween 80) were obtained from ICI Americas Inc. 
(Wilmington, Del.). 
Poly(d,l) lactic acid (Mw 100,000) was also obtained 
from Birmingham Polymers Inc. (Birmingham, Ala.). 
d.1-Chlorpheniramine maleate, procainamide hydro 
chloride, and promazine hydrochloride were obtained 
from Sigma Chemical Co. (St. Louis, Mo.). Diphenhy 
dramine hydrochloride (USP/NF) was also obtained 
from Spectrum Chemical Mfg. Co. (Gardens, Calif.). 
Recombinant human tumor necrosis factor (TNF) was 
obtained from Dainippon Pharmaceutical Co., Ltd. 
(Osaka, Japan). 
Even though the invention has been described with a 
certain degree of particularity, it is evident that many 
alternatives, modifications, and variations will be appar 
ent to those skilled in the art in light of the foregoing 
disclosure. Accordingly, it is intended that all such 
alternatives, modifications, and variations which fall 
within the spirit and scope of the invention be embraced 
by the defined claims. 
The following examples are presented to describe 
preferred embodiments and utilities of the present in 
vention, but should not be construed as limiting the 
claims thereof. 
Example 1-Preparation of Multi-phase Microspheres 
Example 2-Water-Soluble Molecular Compound 
Loading Efficiencies with TNF-Comparison be 
tween Multi-phase and Conventional Microspheres. 
Example 3-Microsphere Formation and Drug Load 
ing Efficiencies with Water-Soluble Molecular Com 
pounds with Varying PLA and PLGA Polymer Con 
centrations. 
Example 4-Microsphere Water Soluble Molecular 
Compound Loading Efficiency and Span 80 Concen 
tration. 
Example 5-Comparison of Drug Loading and of In 
Vitro Dissolution in Conventional vs. Multi-phase 
Microspheres with CPM and Brilliant Blue. 
Example 6-Comparison of Loading Efficiencies, Re 
lease Properties and Morphology of Conventional 
and Multi-phase PLGA Microspheres with CPM, 
DPH, PMZ, PRC and Brilliant Blue. 
Prophetic Example7-Proposed Methods for Preparing 
Multi-Phase Microspheres with Water-Soluble Pep 
tides and Proteins and Multi-phase Microspheres of 
Less than 150 Size. 
EXAMPLE 
Preparation of Multi-phase Microspheres 
The present example is provided to demonstrate one 
particularly preferred method by which the multi-phase 
microspheres of the present invention may be prepared 
with virtually any molecular compound. The multi 
phase microspheres prepared in the present example 
were found to have a particle size of between about 
150l to 300. However, particles of smaller size (e.g., 
between 50 to 100, less than 150p) may be obtained 
through modifying the presently described system as 
outlined in Prophetic Example 7. 
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Molecular compounds that are soluble and stable in 
water (e.g. CPM, PMZ, DPH, PRC) may be prepared 
as an aqueous solution, which is then dispersed in an oil 
to form a microemulsion. Molecular compounds which 
are unstable (subject to denaturation in a water mixture 
with an organic solvent) (e.g., TNF), the final micro 
spheres may be dried under vacuum to remove the 
water from the microspheres. Alternatively, a water/oil 
microemulsion of the drug may be prepared and the 
microemulsion lyophilized to remove or decrease the 
water content prior to emulsification in the dispersion 
oil and acetonitrile-polymer solution. This system 
would result in finely dispersed particles of the drug in 
the oil phase prior to the encapsulation process. 
For organic molecules that readily decompose or 
denature in the presence of moisture, these agents 
should be finely dispersed in the fixed oil prior to dis 
persing the oil in the acetonitrile solution of the poly 
ne. 
The multi-phase microspheres were prepared by a 
multi-phase solvent evaporation process. The three-step 
emulsification process is described in FIG. 1. The prep 
aration of the W/O emulsion (aqueous solution of a 
water-soluble molecular compound in a fixed oil (e.g., 
soybean oil or safflower oil)) constitutes step 1. This 
results in a unique "microemulsion' of the oil and the 
compound contained within a number of fine droplets. 
The W/O-in-acetonitrile (W/O/"O") emulsion was 
prepared by dispersing the W/O emulsion in the polym 
er-acetonitrile solution as outlined in step 2. The poly 
mer solvent, acetonitrile, was removed from the 
W/O/"O" emulsion by evaporation under atmospheric 
pressure. In order to achieve the finished product repre 
sented in step 3, the hardened microspheres were placed 
under reduced pressure for complete removal of the 
acetonitrile. Formulations for the microspheres contain 
ing molecular compounds in the emulsion system are 
shown in table 1. 
TABLE 
The Formula For Multi-Phase Microspheres 
Theoretical 
Phases Elements amounts (mg) 
Core (W/O Water Brilliant blue 1.07 (30.5) 
emulsion) (or CPM) 
Gelatin 0.83 
Tween 80 3.33 
Distilled Water 79.14 
Oil Aurninum mono- 5.00 
Steatate 
Span 80 10.00 
Soybean oil 235.00 
Wall PLGA or PLA 666.0 
Polymer 
Total weight 1000.00 
More specifically, the soybean oil in step 1 (FIG. 1) 
was heated to 140 C/ to dissolve the aluminum stearate 
(2% w/w), after which the oil phase was cooled to 40 
C. The aqueous phase (25 ml) containing the water-sol 
uble molecular compound, in this case brilliant blue or 
CPM, and gelatin (1% w/w), and Tween 80 (4% w/w) 
was poured into the oil phase (75 ml) containing Span 
80 (4% w/w) and agitated in order to obtain a coarse 
W/O emulsion. The W/O emulsion was then homoge 
nized with a microfluidizer (model M-110T) until a fine 
microemulsion was obtained. 
In step 2, the polymer and polymer solvent solution 
was added. PLA or PLGA are the preferred biodegrad 
able polymers. Each of these polymers (about 3 grams) 












grams, Fischer Scientific Co.). The W/O microemul 
sion (drug gelatin, Tween 80, Span 80, soybean oil, 
aluminum stearate) was poured int this polymer 
acetonitrile solution and dispersed to form a W/O/"O" 
emulsion (multiple emulsion). 
It was noted that at the final drying step under re 
duced pressure (48 hrs) (Step 3, FIG. 1), there may 
occur "dehydration' of the water/oil emulsion incorpo 
rated in the multi-phase microspheres. 
In step 3, the W/O/"O" emulsion was poured gently 
through a narrow nozzle into agitated light mineral oil 
containing Span 80 to form a W/O/"O"/O multiple 
emulsion (the "dispersion' medium). The multiple 
emulsion system was agitated by a stainless steel propel 
ler for 24 hours to evaporate and remove the acetoni 
trile. The hardened microspheres were filtered using 
nylon screens; washed with n-hexane, Tween 80 solu 
tion (2% w/v) and distilled water. For further solvent 
removal, the microspheres were dried under reduced 
pressure for 48 hours. The schematic features of the 
multi-phase microsphere preparation protocol are illus 
trated in FIG. 1. 
Adjustment of Preparative Conditions for Multiple 
Emulsion Solvent Evaporation 
Span 80 and Tween 80 were used as emulsifying 
agents to make a water (aqueous water soluble molecu 
lar compound solution) in soybean oil (W/O) emulsion. 
This W/O emulsion was found to be unstable in the 
PLA or PLGA-acetonitrile solutions (step 2), and the 
aqueous phase of the emulsion was readily released into 
the acetonitrile solution due to phase inversion. The 
addition of aluminum monostearate to soybean oil was 
effective in preventing phase inversion with the W/O 
emulsion by increasing the viscosity and plasticity of 
the soybean oil. Aluminum monostearate has been pre 
viously used as a hardening agent for oils in non-aque 
ous penicillin G suspensions for injections. The levels of 
Span 80 and Tween 80 were optimized to decrease the 
size of the aqueous phase in the W/O emulsions pre 
pared by homogenization. 
EXAMPLE 2 
Molecular Compound Loading Efficiencies with 
TNF-Comparison Between Multi-phase Microspheres 
and Conventional Microspheres 
The present example is provided to demonstrate the 
applicability of the presently disclosed multi-phase mi 
crosphere system for use with virtually any protein 
which is not necessarily stable in the aqueous phase of a 
"W/O' emulsion which contacts with a polymer sol 
vent, such as acetonitrile. The multi-phase microsphere 
system of the present example employs TNF as an ex 
emplary protein. 
Multi-phase TNP Microspheres 
TNF is a molecular compound which is unstable in 
water, and which will become denatured if placed in an 
aqueous phase of a "W/O' emulsion in an acetonitrile 
polymer solution. This is because the outer acetonitrile 
will penetrate into the aqueous phase. Multi-phase mi 
crospheres were prepared by first preparing a TNF 
solution, emulsifying the TNF solution in cyclohexane, 
and lyophilizing the emulsification to form a fine pow 
der. This powder was dispersed in the oil containing 
aluminum monostearate. This oil suspension was then 
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used for the preparation of the multi-phase micro 
spheres of TNF. 
Alternatively, a microsphere may be prepared sub 
stantially according to the steps outlined in FIG. 1, 
except that the final microspheres must be dried under 
vacuum to remove the water from the microspheres, 
thus enhancing the stability of the TNF. 
Conventional TNF Microspheres 
Conventional microspheres with TNF were prepared 
by dissolving the TNF in a polymer and acetonitrile 
solution to provide a mixture. The mixture was then 
poured into mineral oil containing Span 80 through a 
narrow nozzle, and agitated for 48 hours with a stainless 
steel propeller. After this stage, the obtained micro 
spheres were processed by substantially the same re 
maining steps outlined in FIG. 1 (step 3, FIG. 1). 
Because TNF is denatured in the presence of water, 
the final product microspheres of both the multi-phase 
and conventional microspheres should be free of mois 
ture in order to maintain the stability of the protein. 
The amount of TNF employed in the microspheres of 
the present example was about 5 mg. 
TNF employed for preparing both the convention 
and multi-phase microspheres was obtained from Dai 
nippon Pharmaceutical Co., Ltd., Osaka, Japan, recom 
binant human tumor necrosis factor. TNF has a molecu 
lar weight of 18,000 and an isoelectric point of 5.9. The 
TNF of the present example is stable at pH 6 to 9. 
The above-described multi-phase and conventional 
microspheres were prepared using the biodegradable 
polymer PLGA. Microspheres prepared in batch 1 and 
batch 2 both employed the same lot of TNF obtained 
from Dainippon Pharmaceutical Co. 
The loading efficiency of TNF into multi-phase and 
conventional (i.e., matrix) microspheres was measured 
and compared. The data obtained is presented in Table 
2. 
TABLE 2 
Comparison of TNF loading efficiency between multi 
phase and conventional microspheres. 
Type of Particle Loading Weight 
microspheres Batch size range efficiency Fraction 
parameter number D E 2 W 
Multi-phase 100-250 un 78.5% 0.44 
250-500 100.2 0.526 
100-500 89.92 1,000 
2 100-250 85.5 0.757 
250-500 99.8 0.243 
00-500 88.92 000 
over all 100-250 82.03 0.616 
mean of 250-500 100.33 0.384 
and 2 100-500 89.43 1,000 
Conventional 100-250 m 53.6% 0.478 
250-500 70,6 0.522 
100-500 69.82 .000 
2 00-250 68.7 0.594 
250-500 71.6 0.405 
100-500 62.52 000 
over all 100-250 6.23 0.536 
mean of 250-500 13 0.464 
1 and 2 100-500 66.23 1.000 
l Solvent evaporation (step 3) was carried out at agitating speed at 400 rpm 
(batch-I) and 500 rpm (batch-2). 
2 Loading efficiency (100-500 un) was calculated as follows: 
E%(100-500) = 
E%00-250) x FOO-2SO - E (250-s00 x F2SOSOC) 
F100-250) - F(250-500) 
3 Loading efficiency (a-bin) was calculated as follows: 
E%(a-b) = (a-b) of batch- 2 %(a-b) of batch-2 
The TNF loading efficiency in batch 1 of the multi 













efficiency for batch-2 multi-phase microspheres was 
88.9%. The mean TNF loading efficiency into multi 
phase microspheres of both batch 1 and batch 2 prepara 
tions was 89.4%. The TNF loading efficiency observed 
in conventional (matrix-type) microspheres, batch 1 
was 69.8%. TNF loading efficiency in batch 2 conven 
tional (matrix) microspheres was 62.5%. The average 
TNF loading efficiency into conventional (matrix) mi 
crospheres was 66.2%. These data demonstrate a signif 
icant enhancement in TNF loading efficiency using 
multi-phase microspheres, as compared to conventional 
matrix type microsphere systems. 
Batch 1 microspheres were prepared using an agitat 
ing speed of 400 rpm at step 3 (see FIG. 1). Batch 2 
microspheres were prepared at an agitating speed of 500 
rpm at step 3 (see FIG. 1). The same lot of TNF ob 
tained from Dainippon Pharmaceutical Co. Ltd. was 
used in the preparation of both batches of TNF micro 
spheres. 
EXAMPLE 3 
Microsphere Formation and Loading Efficiencies With 
Water-soluble Molecular Compounds With Varying 
PLA and PLGA Concentrations 
The present example is provided to demonstrate the 
effect of polymer concentrations on microsphere forma 
tion and on the optimization of microsphere drug load 
ing efficiency and the dependence thereon on particular 
polymer concentrations. 
The effect of changes of PLA and PLGA concentra 
tions in acetonitrile (polymer solvent) on microsphere 
drug loading efficiency and the appearance of multi 
phase microspheres was studied. A concentration of 
0.25% w/w of Span 80 was included in the "dispersion" 
medium of light mineral oil and Span 80. The steps for 
preparing the microspheres were substantially the same 
as that outlined in FIG. 1. 
Microsphere Formation and Polymer Concentration 
Spherical multi-phase microspheres were obtained at 
PLA/acetonitrile concentrations between 28.6 and 
33.3% w/w and at concentrations between 22.2 and 
30.8% w/w for the PLGA. No aggregation of the parti 
cles was observed between these ranges of polymer 
concentrations. 
At low (below about 22.2% for PLA, below about 
16.7% for PLGA) concentrations of PLA or PLGA in 
acetonitrile, it was difficult to disperse the W/O emul 
sions (the microemulsion) into the polymer solution, 
and therefore multi-phase microspheres containing the 
W/O emulsions were not obtained. 
As the concentration of the polymers in acetonitrile 
increased to at least about 16% (the lowest limit being 
about 22.2% for PLA and about 16.7% for PLGA), 
dispersion of the W/O emulsion (microemulsion) drop 
lets in the polymer-acetonitrile solution improved. This 
was attributed to a synergistic effect of the surface 
protecting characteristics of the polymer, increased 
viscosity of the polymer/acetonitrile solution, and can 
cellation of the density difference between the W/O 
emulsion (microemulsion) and the acetonitrile medium 
by the addition of the polymer. At high polymer con 
centrations, the microspheres aggregated during the 
process of the solvent evaporation (FIG. 1, step 3). 
Relatively large and viscous polymer-acetonitrile solu 
tion droplets containing the W/O emulsions resulted in 
irregularly shaped unhardened masses. These masses 
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were observed to cause adhesion to other masses and 
unhardened microsphere beads. 
The highest polymer concentrations in acetonitrile 
that could be used without aggregation occurring were 
about 33.3% w/w and about 30.8% w/w for the PLA 
and the PLGA, respectively. These polymer concentra 
tions were selected in order to minimize the acetonitrile 
evaporation time. 
Water-Soluble Molecular Compound Loading 
Efficiency and Polymer Concentration 
Loading efficiencies of brilliant blue, DPH, PMZ, 
and PRC into the multi-phase microspheres were exam 
ined with various amounts of the W/O emulsions (mi 
croemulsion) dispersed in 3.25 g of PLGA-acetonitrile 
solution (30.8% w/w) containing 1.00 g of PLGA. The 
results in FIG. 12 depict the drug loading efficiencies 
versus the weight of the W/O emulsions when the mul 
ti-phase microspheres were prepared using light mineral 
oil (the "dispersion' medium) containing 0.25% of Span 
80. The W/O emulsion weights ranging from 0.25 to 
0.75 g gave relatively high loading efficiencies (280%). 
Drug loading efficiency levels in excess of 70% were 
obtained with W/O emulsion weights up to 1.00 gram) 
when DPH, PMZ, and PRC were loaded into the multi 
phase microspheres. However, the loading efficiency of 
brilliant blue decreased significantly when the weight of 
the W/O emulsion increased to 1.0 g. 
The water in the internal aqueous phase of the W/O 
emulsions began to diffuse into the surrounding polym 
er-acetonitrile phase as the quantity of the W/O emul 
sion in the PLGA-acetonitrile solution increased to 
above 0.5g. This occurred during the agitation steps in 
the process, resulting in an increase in solubility of the 
water-soluble molecule molecular compounds DPH, 
PMZ, and PRC into the surrounding polymer-acetoni 
trile phase. During the solvent evaporation process, the 
drug compounds that diffused into the polymer-acetoni 
trile phase diffused out of the unhardened multi-phase 
microspheres. 
The inventors postulate that the higher water content 
(93.7% w/w) in the aqueous phase of the W/O emul 
sion containing brilliant blue precipitated a significant 
loss in drug loading efficiency. The loading efficiencies 
of DPH, PMZ, and PRC were reduced only slightly by 
the increasing amounts of the W/O emulsions, which 
contained 44.5, 47.3, and 41.1% w/w of water in their 
aqueous phases, respectively. The percentage of water 
is limited by the saturation concentration of drugs or 
compounds. Most preferably, the percent of water 
(w/w) to be included in the aqueous phase of water 
soluble drugs should not exceed 50% for optimal drug 
loading efficiency. 
EXAMPLE 4 
Water Soluble Molecular Compound Loading 
Efficiency and Span 80 Concentration 
The present example is provided to demonstrate the 
effect of varying concentrations of Span 80 in the "dis 
persion' media on the drug loading efficiency of water 
soluble molecular compounds into the multi-phase mi 
crospheres of the present invention. The microspheres 
were prepared according to the protocol outlined in 
FIG. 1. 
The loading efficiency of brilliant blue, CPM, DPH, 
PMZ, and PRC in PLGA multi-phase microspheres 
prepared in mineral oil (dispersion media) containing 












The loading efficiency of brilliant blue had a maximum 
value of about 904 at 0.25% w/w of Span 80 and de 
creased significantly at concentrations of Span 80 above 
0.5% w/w. Within the Span 80 concentrations ranging 
from 0.25 to 0.5% w/w, the loading efficiencies of the 
drugs DPH, PMZ, PRC and CPM exceeded 90% and 
gradually decreased to 50-70% as the Span 80 concen 
trations increased to 2.0% w/w. 
The optimum concentration of Span 80 for this sys 
tem was between 0.25 and 0.5% w/w for 804 or greater 
drug loading efficiency. The loading efficiency reduc 
tions, which were observed with each of the tested 
drugs, were attributed to the increased solubilizing 
properties of the evaporation (i.e., "dispersion') me 
dium containing above 0.50% of w/w Span 80. 
When the concentration of Span 80 was less than 
0.25% w/w, the dispersed droplets of PLGA-acetoni 
trile solution, including the W/O emulsion of brilliant 
blue and CPM, were unstable, resulting in fusion and 
agglomeration of the droplets and a decrease in the 
loading efficiencies of brilliant blue and CPM. The 
W/O emulsions containing brilliant blue and CPM were 
disrupted due to the physical stresses of fusion and 
agglomeration. The loading efficiencies of micro 
spheres containing CPM and DPH exceeded 100% at 
low concentrations (less than 0.25% w/w) of Span 80. 
This was due to the removal, during the "separation" 
and "drying" stages in the process (see FIG. 1), of the 
PLGA beads that were too small to contain the W/O 
emulsion. Polymer beads are not able to incorporate 
W/O emulsion droplets which are larger than the beads 
themselves. Such "too small' polymer beads pass 
through a nylon screen and are removed from the prod 
ucts (step 3). Thus, the final products have an increased 
amount of the W/O emulsion in them. 
The microspheres containing other drugs (PMZ, 
PRC) did not show the drug loading efficiency loss or 
significant aggregation at the low (0.25% or less) con 
centrations of Span 80. The mineral oil (dispersion me 
dium) obtained after solvent evaporation of brilliant 
blue containing multi-phase microspheres was clear, 
and the released brilliant blue was completely solubi 
lized. However, when CPM, DPH, PMZ, and PRC 
were loaded in the microspheres, small quantities of 
crystals or solid drug particles of the drugs appeared in 
the mineral oil and precipitated with the microspheres 
at each concentration level of span So in the mineral oil. 
The theoretical content of brilliant blue, CPM, DPH, 
PMZ and PRC in the microspheres was 1.07, 30.5, 44.5, 
47.3, and 41.6 mg/g, respectively. 
The hardened microspheres prepared with a mineral 
oil and > 0.254 Span 80 dispersion medium demon 
strated a reduced loading efficiency of brilliant blue. 
The other drug diffusion rates from the unhardened 
microspheres were not influenced by the Span 80 con 
centration in the mineral oil. In contrast to the brilliant 
blue, the solubilities of the DPH, PMZ, PRC, and CPM 
drugs in the mineral oil phase were lower than the con 
centration of the drugs that diffused out of the unhard 
ened microspheres. This allowed the drug crystal pre 
cipitation to act as a rate limiting step and to restrict the 
diffusion of drug from unhardened microspheres into 




Comparison of Drug Loading and In Vitro Dissolution 
in Conventional VS. Multi-phase Microspheres With 
CPM and Brilliant Blue 
The present example is provided to demonstrate and 
compare the dissolution properties and drug loading 
efficiencies of conventional microspheres and multi 
phase microspheres which contain either a water-solu 
ble drug, such as CPM (chlorpheniramine maleate) or a 
water-soluble dye, such as brilliant blue. The particular 
water-soluble drug CPM and water-soluble dye, bril 
liant blue, are used to demonstrate the applicability of 
employing the disclosed multi-phase microspheres with 
virtually any water-soluble drug, protein, peptide or 
dye. 
Multi-Phase Microspheres 
Multi-phase microspheres of poly (d,l-lactic acid) 
(PLA) or poly (d.l-lactic co-glycolic acid) (PLGA) 
containing a water soluble molecular compound solu 
tion in oil (W/O) emulsion were prepared by the multi 
ple emulsion solvent evaporation technique described in 
Example 1. Either CPM or brilliant blue was employed 
as the water-soluble molecule, to which was added 
gelatin (about 1% W/V in aqueous phase, Fisher Scien 
tific Company), Tween 80 and distilled water. The fixed 
oil with which the water-soluble molecular compound 
was mixed was soybean oil. The soybean oil also in 
cluded an amount of about 2.0% W/W aluminum mon 
ostearate to which about 4% w/w Span 80 was added in 
about 93.5% soybean oil. The above two -mixtures 
were combined and agitated to form a "microemul 
sion'. 
The polymer/solvent mixture was then prepared, 
into which the "microemulsion' was poured and mixed 
together in a dispersion medium of mineral oil and Span 
80. Acetonitrile was used as the polymer solvent. A 
mixture of light mineral oil and Span 80 was employed 
as the dispersion medium. 
The polymeric multi-phase microspheres contained 
oil-drug reservoirs throughout the polymer matrix, 
with the water-soluble drug being contained within an 
aqueous dispersed phase inside the oily droplet. 
Conventional Microspheres 
Conventional PLGA microspheres containing either 
CPM or brilliant blue were prepared by an acetonitrile 
in-oil (W/O) emulsion solvent evaporation technique 
substantially as described by Jalil and Nixon3. The 
CPM and the PLGA were dissolved in the acetonitrile 
("W" phase). Similarly, a preparation of brilliant blue 
and PLGA were dissolved in acetonitrile. Light mineral 
oil was used as the evaporation (dispersion) medium in 
both preparations (O phase). So formed, the resulting 
conventional CPM or brilliant blue containing micro 
spheres were prepared to provide contact with the 
polymer matrix. 
A. Comparison of brilliant blue and CPM drug load 
ing efficiency and dissolution characteristics of multi 
phase and conventional microspheres 
1. Drug Loading Efficiency 
The drug loading efficiencies of brilliant blue and 
CPM in multi-phase and conventional microspheres are 
shown in FIG. 14. Approximately the same theoretical 
levels of both agents were loaded into preparations by 
each process. The drug loading efficiencies of the multi 












ventional microspheres prepared from acetonitrile and 
mineral oil. 
Minuscule levels of water-soluble CPM and brilliant 
blue were found when the microspheres were prepared 
using the traditional non-aqueous (drug/acetonitrile 
solution-in-mineral oil) ("W"/O) system. In contrast, 
the loading efficiency of CPM in particular was signifi 
cantly higher in the multi-phase microspheres than in 
the conventional microspheres (FIG. 14-B) (Multi 
P=1004 loading eff. vs. Cony.=about 40% loading 
eff.). 
The drug loading efficiencies of both types of micro 
spheres decreased when less than or 0.25% W/W of 
Span 80 was added to the mineral oil dispersion me 
dium. However, 0.251% Span 80 (W/W) was found by 
the present inventors to provide acceptable results. The 
multi-phase microspheres effectively prevented both 
brilliant blue and CPM from "leaking out” into the 
mineral oil during the solvent evaporation process. 
Since the polymer walls were in the liquid state, the 
drug (CPM), which was trapped in the W/O emulsion 
consisting of a hardened oil phase, diffused out into the 
evaporation medium at a much slower rate than the 
drug that was dispersed in the unhardened conventional 
microspheres. 
2. Dissolution Study of CPN or Brilliant Blue in con 
ventional vs multi-phase microspheres 
Dissolution rate results observed with the brilliant 
blue and CPM in the conventional and multi-phase 
microspheres appear to be the same. Later onset of 
rapid dissolution with multi-phase microspheres and 
CPM provide a slower drug release system suitable for 
protracted drug delivery regimens. The onset of rapid 
dissolution was relatively the same as between conven 
tional and multi-phase microspheres containing water 
soluble brilliant blue dye. 
However, the onset of most rapid dissolution of 
water-soluble drug (CPM)-containing microspheres 
was almost the same in multi-phase (18.4 (day)) as com 
pared to convention (19.6 day) microspheres. The disso 
lution rate results observed with the brilliant blue and 
CPM in conventional and multi-phase microspheres 
appear in Table 3. 
TABLE 3 
Dissolution Study of CPM or Brilliant Blue in Microspheres 
The estimated onsets of rapid dissolution of 
brilliant blue and CPM from multi-phase and conventional 
microspheres. 
Water-soluble Types of Content Estimated onsets for the 
substances microspheres (mg/g) rapid dissolution (day) 
Brilliant Blue Conventional 0.2 2.7 22.15 (mean) 
1.3 22.6 




CPM Conventional 4.3 19.6 
60. 
27.7 19.6 




Onset for rapid release was not observed. 
B. Comparison of Brilliant Blue and CPM Morphol 
ogy of Multi-Phase and Conventional Microspheres 
A micrograph of the PLGA multi-phase micro 
spheres containing brilliant blue, as observed by trans 
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mitted-light, is shown in FIG. 8-A. The dark areas in 
the microsphere beads are the W/O emulsions contain 
ing brilliant blue, Scattered fine particles seen in the 
polymer wall are brilliant blue particles that have 
leaked out of the W/O emulsions. Cavities were ob 
served in the cross sections of the microspheres under 
reflected light conditions. These results demonstrate 
that the multi-phase microspheres belong to a class of 
hybrid matrix type drug delivery devices not before 
recognized. The distribution of the dye in the PLGA 
microspheres prepared by the conventional method is 
seen in FIG. 8-B. 
The outer surface and cross sections of the multi 
phase PLGA microspheres containing brilliant blue 
were observed by SEM (FIG. 5-A and 5-B, respec 
tively). The smaller "pock'-like depressions seen at the 
surface of some microspheres are postulated to have 
been created during the final solvent removal process 
(FIG. 5-B). When the multi-phase microspheres were 
placed under a high vacuum to remove residual solvent, 
the vaporization of residual acetonitrile and partial re 
moval of water inside the microspheres caused the sur 
face of the beads to expand in thin or weak areas be 
neath which the W/O emulsions existed (FIG. 5-B). 
The "stretched' areas were observed to result in de 
pressions or irregularities in surface structure when the 
vacuum was removed. 
Cavities found upon cross-sectioning the micro 
spheres were the result of vacuum-induced evacuation 
of the W/O emulsion during the sample preparation 
process for SEM (FIG. 5-A). Some of the particles that 
remained in the cavities resulted from the aqueous 
phase of the W/O emulsion that had previously existed 
in the cavities. 
Conventional microspheres of PLGA containing 
brilliant blue dispersed in the polymer are shown in 
FIG. 15-A and 15-B. These microspheres did not have 
vacuolate structures in their cross sections (FIG. 15-B). 
The conventional microspheres demonstrated a less 
smooth, rough outer surface than the multi-phase mi 
crospheres (FIG. 15-A). 
EXAMPLE 6 
Comparison of Loading Efficiencies, Release 
Properties and Morphology of Conventional and 
Multi-phase PLGA Microspheres With CPM, DPH, 
PMZ, PRC and Brilliant Blue 
The present example is provided to demonstrate the 
superior drug loading efficiencies and slow-drug release 
characteristics of multi-phase microspheres compared 
to conventional microspheres. Morphological differ 
ences between multi-phase and the conventional micro 
spheres is also described and demonstrated. 
The multi-phase microspheres were prepared as de 
scribed in Example 1. Conventional microspheres were 
prepared as described in Example 5. Each type of mi 
crosphere was prepared with one of each of the water 
soluble molecular compounds brilliant blue CPM, 
DPH, PMZ, or PRC. However, it is expected that vir 
tually the same results would manifest with any other 
water-soluble molecular compound, including biologi 
cally and pharmacologically potent peptides and prote 
S. 
Morphological properties of the multi-phase PLGA 
microspheres during in vitro dissolution studies were 












spheres which included the water-soluble molecular 
compound CPN, DPH, PMZ, PRC, or brilliant blue. 
The multi-phase microspheres showed a slow drug 
release through cracks or failures on surface of the 
beads as the first stage and a rapid release stage as the 
second stage of dissolution. Porous sponge-like struc 
tures were seen in the polymer wall of both types of 
microspheres after 2 weeks although the outer surface 
of the beads remained almost intact after this time per 
iod. The water-soluble compound dissolution rate of the 
conventional microspheres increased as the drug con 
tent of the conventional microsphere increased. How 
ever the multi-phase microspheres demonstrated a dis 
solution rate which was independent of the drug con 
tent. 
While the multi-phase microspheres demonstrated 
slower drug release properties that did the conventional 
microspheres, the polymer PLGA degradation rate of 
the multi-phase and the conventional microspheres 
were almost the same. 
A. Determination of Drug Content in Microspheres 
Water-soluble molecular compounds loaded into the 
conventional and multi-phase microspheres included 
brilliant blue, chlorpheniramine maleate (CPM), di 
phenhydramine hydrochloride (DPH), promazine hy 
drochloride (PMZ), and procainamide hydrochloride 
(PRC). The microspheres were first dissolved in methy 
lene chloride. The brilliant blue remaining in the micro 
spheres was extracted by distilled water, CPM was 
extracted from the microspheres with hydrochloric 
acid (0.01N) in similar fashion. The water-soluble drugs 
were extracted with the same procedure using dilute 
hydrochloric acid (0.01N HCl). 
After sufficient agitation and partitioning time, the 
aqueous solutions containing the extracted drugs or dye 
were clarified by centrifugation at 2,000 rpm for 20 min. 
The drug content of each sample was evaluated by 
assay using uv.-visible spectroscopy. The experimental 
drug loading efficiencies were calculated as a percent 
age of the theoretical drug content. 
B. in Vitro Dissolution Studies 
The multi-phase and the conventional microspheres 
(100-300 mg, 250-500 um) were placed in 25 ml of pH 
7.4, 0.01 M phosphate buffered saline (PBS) contained 
in a 30 ml test tube. The microspheres in the PBS were 
shaken using a rotating bottle apparatus (20 rpm) in a 
water bath at 37 C. Samples (5 ml) were withdrawn at 
appropriate time intervals using a glass syringe fitted 
with a nylon screen (50 um) held in a polyethylene 
housing. After each withdrawal, the sample was replen 
ished with 5 ml of PBS. Each sample was filtered using 
a 0.45 um membrane filter. Absorbance of the samples 
were measured after appropriate dilutions. 
1. Conventional Microspheres 
Lag time stages were observed in the release profiles 
of the conventional microspheres. This was attributed 
to the time required for water to penetrate into the 
polymer matrix and for sufficient polymer degradation 
to form aqueous channels through which the drug 
could diffuse out of the microspheres. During this lag 
time period, the erosion of the polymer wall of the 
conventional microspheres developed to form failures 
or cracks which were seen between the lamellas (FIG. 
6-B). These lamellas were created by the polymer ero 
sion along the discontinuous interfaces between the 
laminated PLGA precipitates which were hardened 
concentrically from the surface to the center of the 
beads. After 2 weeks, the porous sponge-like structures 
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were observed in the polymer wall and the pores had 
developed toward the center of the beads. Some shal 
low portions beneath the surface of the beads had al 
ready eroded and evacuated. However, the surface 
portions of the beads remained almost intact even after 
2 weeks (FIG. 9-A). 
The second stage of the drug dissolution was thought 
to take place once aqueous channels had formed suffi 
ciently for drug to diffuse out of the beads through the 
failures or the thin portions of the eroded surface. 
The rate of drug release from conventional micro 
spheres varied depending upon the drug content of the 
microsphere (see FIG. 3-A). In contrast, the rate of 
drug release from the multi-phase microspheres was 
relatively independent of the drug content of the micro 
sphere (see FIG. 3-B). 
2. Multi-Phase Microspheres 
Slow dissolution (the first stage) of brilliant blue from 
the multi-phase microspheres was observed. This is 
hypothesized as being due to drug diffusion into the 
outer fluid from the W/O emulsion of the microspheres 
through thin portions of the polymer wall (see arrow in 
FIG. 5-A). Some of the thin areas of the microsphere 
surface had "dimples' which were observed on the 
multi-phase microspheres by SEM before the dissolu 
tion test (FIG. 5-B). These "dimples' were created 
during the final solvent removal process. When placed 
under a high vacuum, the microspheres were expanded 
in unhardened and thin areas of the surface. Once the 
vacuum was removed, the stretched surface portions 
resulted in the depressions or "dimples'. 
As the polymer wall swelled during the in vitro disso 
lution, highly drug permeable areas in the polymer 
walls of the multi-phase microspheres permitted the 
release of the drugs (see FIG. 7-A, thin walled portions 
at surface). 
After two weeks, many pores had merged and 
formed porous sponge-like structures inside the beads 
(FIG. 7-B). These pores connected with each other, 
forming channels through which the water-soluble mo 
lecular compounds could diffuse (see FIG. 7-C and 
FIG. 7-D). 
The internal surface on the inside of the cavities, in 
which the W/O emulsions once existed, did not appear 
eroded. The external surface of the multi-phase micro 
spheres, in contacting with the mineral oil, also re 
mained nearly intact as did the surface of the conven 
tional microspheres. 
A description of the morphological changes of the 
Conventional and the Multi-phase Microspheres during 
in vitro Dissolution Study follow in Section C. 
C. Morphology of Microspheres and Polymer Degra 
dation Scanning electron microscopy (SEN)-Morpho 
logical Analysis 
microspheres were coated with gold-palladium for 70 
seconds under an argon atmosphere using a cold sputter 
module in a high-vacuum evaporator equipped with an 
omni-rotary stage. Samples were examined with a 
JOEL model 35 scanning electron microscope at 25 
... KV. 
PLGA Molecular Weight Determination by Gel 
Permeation Chromatography (GPC) 
Molecular weight of PLGA was determined by GPC 
in tetrahydrofuran using a set of three Ultrastyragel 
columns (Waters) with nominal pore size of 10, 102, 
and 10 nm, and a flow rate of 1 ml/min. The molecular 
weights were evaluated by elution volume against poly 












1. Conventional microspheres 
FIG. 4-A and 4-B show the cross-sections and the 
outward appearance, respectively, of the conventional 
microspheres containing brilliant blue (0.2 mg/g) which 
were observed after one week dissolution in vitro. The 
clear polymer walls of the microsphere beads turned 
white due to water uptake. Small pores, in which the 
brilliant blue particles had once existed, and concentric 
lamellar structures like onion peels were observed by 
SEM on the cross-section of the conventional micro 
spheres (FIG. 4-A). These lamellar structures were not 
seen before the dissolution test. FIG. 6-C shows the 
cross sections of the microspheres observed after 2 
weeks of the dissolution test. Erosion of the internal 
polymer wall had developed and porous sponge-like 
structures appeared. The inside of the microspheres 
were partially evacuated. However, the superficial por 
tions of the beads remained almost intact. The rapid 
dissolution of the brilliant blue started around this stage. 
After 4 weeks, the porous structures of the internal 
polymer wall had mostly disappeared, but the polymer 
shells and residual masses still remained (FIG. 6-D). 
2. Multi-Phase microspheres 
FIG. 7-B shows a cross-section of the multi-phase 
microspheres containing brilliant blue (0.3 mg/g) ob 
served by SEM after a week. The lamellar structures, 
which were seen on the cross-section of the conven 
tional microspheres after a week, were not observed. 
The cross-sectional surfaces observed under reflected 
light appeared smooth and white due to the water up 
take (FIG. 5-A). The brilliant blue dissolved gradually 
through cracks which were formed by erosion of the 
polymer on the surface at this stage. Dark spots of the 
penetrated brilliant blue diffused out of the W/O emul 
sions in the polymer beads, as seen on the surface of the 
microspheres. 
FIG. 7-C shows a cross section of the multi-phase 
microspheres after 2 weeks of dissolution. Many pores 
appeared in the cross-sections of the polymer wall form 
ing porous structures. The pores were larger than those 
of the conventional microspheres. Some of these pores 
became larger due to the erosion, and connected with 
each other to form aqueous channels through which 
drug could diffuse. However, the internal erosion of the 
polymer beads did not extend to the cavities which had 
contained the W/O emulsions. 
After 4 weeks, when about 70% of the brilliant blue 
had been released, the superficial polymer walls and the 
porous structures of the microspheres remained (FIG. 
7-D). 
Molecular Weight Changes of PLGA of the 
Microspheres during the Release Test 
Prior to the dissolution test and after 1, 2 and 4 weeks, 
the molecular weight of PLGA of the microspheres 
containing brilliant blue and CPM were determined by 
gel permeation chromatography (GPC) already de 
scribed. FIG. 10 indicates the semi-log plots for-molec 
ular weight changes of the residual solid PLGA of the 
conventional and the multi-phase microspheres contain 
ing brilliant blue (FIG. 10-A) and CPM (FIG. 10-B). 
The PLGA polymer degradation rates of the conven 
tional and multi-phase microspheres were virtually the 
same when the microspheres contained either brilliant 
blue or CPM. Thus, the inclusion of a water soluble 
compound and the particular amount of same in the 
W/O emulsion (microemulsion) in the multi-phase mi 
crospheres did not affect the PLGA degradation. In 
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addition, the water soluble molecular compounds con 
tained within the microspheres did not appear to affect 
the degradation of the polymer. 
D. PLGA Degradation Properties During In Vitro 
Dissolution Test 
The polymer walls which contacted with oil phase 
(soybean oil of the W/O emulsion in the microspheres 
and mineral oil used as the solvent evaporation medium 
for the preparation) seemed relatively stable compared 
to other portions of the polymer wall. However, the 
rates of the molecular weight reduction of PLGA in 
residual portion of each types of the microspheres were 
almost the same (see FIG. 10). Span 80, which was 
added to both the soybean oil and the mineral oil, may 
be adsorbed on the surface of the polymer beads causing 
protection from hydrolysis. In order to discuss the 
mechanism of the multi-phase microsphere erosion, 
further investigation of the polymer degradability and 
possible interactions with ingredients are needed. 
The PLGA multi-phase microspheres demonstrated a 
two-stage release property which was independent of 
the brilliant blue and CPM content and their physio 
chemical characteristics, while the release profiles of 
the conventional matrix type microspheres had lag time 
and were affected by the drug content and the brilliant 
blue. 
PROPHETIC EXAMPLE 7 
Methods for Preparing Small Multi-phase Microspheres 
With Molecular Compound Therapeutic Agents 
The present prophetic example is provided to de 
scribe methods whereby the particle size of the micro 
spheres may be reduced so as to provide a preparation 
of small (i.e., less than 1501, preferably between about 
50cc to about 100) multi-phase microspheres. The 
present example will also outline methods whereby 
particular water soluble or partially water soluble pro 
teins and peptides may be incorporated into the de 
scribed multi-phase microsphere system. 
Drugs such as decongestants, antihistamines, biologi 
cal response modifiers (such as the interferons, interleu 
kins, NAF (macrophage activating factor), SCF, TDF, 
EGF, EPO, TPA, ANP (arterial natriuretic peptide), 
etc.), antiviral agents (idoxuridine, amantadine, inter 
feron, etc.), hemoproteins (P-450 enzymes, etc. ), hor 
mones (insulin, LHRH), enzymes (urokinase), may be 
prepared as part of a "microemulsion' in, for example, 
a volume of soybean oil, and then incorporated into the 
described multi-phase microsphere protocol outlined in 
Example 1 and FIG. 1. 
The following particular modifications of that proto 
col will be required to facilitate the most efficacious 
preparation of multi-phase microspheres containing 
proteins and peptides: adjustment of the pH of the aque 
ous phase (which includes the particular water soluble 
drug) to the isoelectric point of the particular water 
soluble molecular compound. Stabilizing or protecting 
agent against degradation, denaturation, etc., may be 
necessary for the pharmacological activity of the pro 
tein, peptides and drug compounds. 
A slight adjustment of the pH of the aqueous phase 
(i.e., the protein inside the oil droplet) and/or stabilizing 
agent for drugs may be necessary in order to enhance 
the stability of the protein (i.e., the microemulsion) 
and/or the solubility of the protein as part of the multi 
phase microsphere preparation may be needed. Such 
may be accomplished by, for example, using the acid, 












mono-basic to adjust the pH of the aqueous solution to 
the desired pH. Buffers such as phosphate buffer, ace 
tate buffer and citrate buffer may also be used to adjust 
pH. By way of example, agents which may be used as 
stabilizing agents include sugars (glucose, sucrose, fruc 
tose, lactose, mannose, mannitol, etc) and polysaccha 
rides (glycogen, starch, CMC-NA (sodium carboxyme 
thycellulose), HPC (hydroxypropyl cellulose), HPMC 
(hydroxypropyl methyl cellulose), HPMCP (hydroxy 
propyl methyl cellulose phthalate), etc.), amino acids, 
peptides (albumin, globulin, gelatin, collagen, etc.), 
mucopolysaccharides (chondroitin sulfate, dextran sul 
fate, etc.), mucopolysaccharides (chondroitin sulfate, 
dextran sulfate, heparin sodium, hyaluronic acid, etc.), 
pluronic, polyethyleneglycols, polyacrylates, PVP 
(polyvinyl pyrollidone), and PVA (poly vinyl acetate). 
A table of some exemplary water soluble and semi 
water soluble proteins and peptides which could be 
used in conjunction with the multi-phase microspheres 
of the present invention appear in Table 4. 
TABLE 4 
Proposed Proteins and Peptides of Microsphere Systems 
Protein/Peptide 
Interferons (IFN-ag,t) 
Macrophage Activating Factor (MAF) 
Interleukins (IL-1,2,3,4,5,6) 
6.8-7.3 (dominant) 5.3-5.8 (minor) 
Colony Stimulating Factor (CSF) 
Tumor Degenerating Factor (TDF) 
Epidermal Growth Factor (EGF) 
Erythropoietin (EPO) 
Tissue Plasminogen Activator (TPA) 
Insulin 5.3-5.35 
Urokinase 
Luteinizing Hormone Release Hormone (LHRH) 
Monoclonal Antibodies 
Superoxide Dismutase (SOD) 
P450 
Bovine Serum Albumin (BSA) 
Oxytocin 
Particular prophetic examples of specific water solu 
ble compounds insulin, interleukin l and 2 follow. 
Insulin Containing Multi-phase Microspheres 
It may be necessary to adjust the pH of the aqueous 
phase contained in the W/O emulsion to the isoelectric 
point of insulin, which is between 5.3 to 5.35 (see 
Merck, 11th ed., p. 4888) in order to accomplish the 
desired stability and/or solubility of the protein. 
The microemulsion so adjusted for pH to solubilize/- 
stabilize the protein, will then be mixed with a polymer 
containing solvent, such as PLA in acetonitrile, and the 
multi-phase microspheres prepared substantially as de 
scribed for the remainder of the procedure in FIG. 1. 
Interleukin Containing Multi-phase Microspheres 
Multi-phase microspheres may be prepared with the 
particular family of proteins known as the interleukins, 
which include IL-1, 2, 3, 4, and 6. It may be necessary 
to adjust the pH of the aqueous phase contained in the 
W/O emulsion to the isoelectric point of the particular 
interleukin species. For example, the isoelectric point of 
the dominant species of interleukin l is between 6.8 to 
7.3. The isoelectric point of the minor species of inter 
leukin 1 is between 5.3 and 5.8. (see, the Merck Index, 
11th Edition, p. 4895-4896). By adjustment of the W/O 
microemulsion or oily suspension of the interleukin, one 
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29 
may accomplish the desired stability and/or solubility 
of this particular agent in the system. 
The aqueous suspension of the interleukin protein so 
adjusted for pH to enhance solubilization/stability of 
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ing solvent such as PLA acetonitrile. The multi-phase 
microspheres may then be prepared substantially as 
described for the remainder of the procedure outlined in 
FIG. 1. 
Proposed Methods for Reducing Multi-phase 
Microsphere Size to Between 50-100. 
The multi-phase microspheres prepared thus far have 
a size of about 150. Microspheres of smaller diameter 
may be prepared by increasing the temperature of the 
oil phase, provided the drug is stable in the emulsion. 
Higher agitation speeds will also be successful if that is 
coupled with a high concentration of polymer in the 
acetonitrile to prevent the loss of emulsion from the 
microsphere. In addition, a dry (lyophilized) emulsion 
system can be used for preparation of multi-phase mi 
crospheres instead of the W/O microemulsion. Where a 
stainless steel propeller device is employed to agitate 
the multiple emulsion, agitation speeds should be in 
creased to, for example, 250, 400, 500 and 600 rpm to 
achieve small (<150p) multi-phase microspheres. 
While those of skill in the pharmaceutical and/or 
polymeric drug delivery chemical arts will be able to 
practice the present invention with the aid of the disclo 
sure provided here, the following references may facili 
tate practice or enhanced understanding of certain as 
pects. Inclusion of a reference in this list is not intended 
to and does not constitute an admission that the refer 
ence constitutes prior art with respect to the present 
invention. The following references are specifically 
incorporated herein in pertinent part by reference. 
1. Bodmeier, R. and McGinity, J. W. (1987), Pharma 
ceutical Research, 4:465. 
2. Bodneier, R. and McGinity, J. W. (1988), J. Microen 
capsulation, 5:325. 
3. Jalil, R. and Nixon, J. R. (1990), J. Microencapsula 
tion, 7:229. 
4. Jalil, R., and Nixon, J. R. (1990), J. Microencapsula 
tion, 7:53. 
5. Csernus, V. J. et al. (1990), Int. J. Peptide Protein 
Res., 35:557. 
6. Okada, H. et al. (1988), J. Pharmacol. Exp. Ther., 
244:744. 
7. Johnson, R. E. et al. (1990), Pharmaceutical Res., 
7(9):S181. 
8. Tsai, D. C. et al. (1986), J. Microencapsulation, 3:181. 
9. Merck Index, 11th Edition, (1983), Windholz et al., 
editors, Merck & Co., Inc., Publishers, pp.4888, 4895, 
4896. 
10. Gilding, D. K., et al. (1979), Polymer, 20:1459. 
11. Leelarasamee, N. et al. (1986), J. Microencapsula 
tion, 3:171-179. 
12. Juni, K. et al. (1985), Chem. Pharm. Bull., 
33(1):313-318. 
13. Cavalier, M., et al. (1986), J. Pharm. Pharmacol., 
38:249-253. 
4. Spenlehauer, G., et al. (1986), J. Pharm. Sci., 
75(8):750-755. 
15. Bodmeier, R. and McGinity, J. W. (1988), Int. J. 
Pharm., 43:179-186. 
16. Lin, S.Y., et al. (1986), Biomat., Med. Devices and 












20. Jalil, R. and Nixon, J. R. (1990b), J. Microencapsula 
tion, 7(1):41-52. 
21. Cohen et al. (1991), Pharm. Res., 9:713-719. 
22. Morris, N.J. and Warburton, B. (1982), J. Pharm. 
Pharmacol., 34:475-479. 
23. Saha, M. V. et al. (1987), J. Microencapsulation, 
4(3):223-238. 
24. U.S. Pat. No. 4,711,782-Okada et al. (1987) 
25. U.S. Pat. No. 4,728,721-Yamamoto et al. (1988) 
26. U.S. Pat. No. 4,954,298-Yamamoto et al. (1990) 
27. Hora et al. (1990), Pharmaceutical Research, 
7(11):1190-94. 
28. U.S. Pat. No. 4.273,920-Nevin (1981) 
29. McGraw-Hill Dictionary of Scientific Terms, 3rd 
edition (1984) McGraw-Hill Publishers, p. 540. 
30. Modern Chemistry, 3d. Edition (1990), Hold, Rine 
hard and Winston, Inc. Publishers. pp. 414-415. 
31. Bodmeier, R., and McGinity, J. W. (1988), J. Micro 
ensapsulation, 4:279. 
32. Makino, K., Ohshima, H., and Kondo, T. (1987) 
Pharmaceutical Research, 4:62. 
33. Williams, D. F., and Mort, E. (1977), J. Bioengineer 
ing, 1:231. 
34. Asano, M., et al (1989), J. Controlled Release, 9:111. 
What is claimed is: 
1. A delivery system for a protein, peptide, or drug 
with biodegradable multi-phase microspheres, said mi 
crospheres comprising a protein, peptide, or drug con 
tained within a fixed oil and an essentially water insolu 
ble, biodegradable polymeric matrix comprised of poly 
lactic acid or polylactic glycolic acid wherein the poly 
meric matrix surrounds the fixed oil of the microsphere 
and wherein the fixed oil contains the protein, peptide, 
or drug. 
2. A delivery system for a water-soluble protein, 
peptide, or drug with biodegradable multi-phase micro 
spheres, said microspheres comprising a microemulsion 
of a water soluble protein, peptide, or drug, a fixed oil 
and a biodegradable, essentially water insoluble poly 
meric matrix of polylactic acid or polylactic glycolic 
acid, said polymeric matrix surrounding the microemul 
sion of fixed oil and the protein, peptide, or molecular 
compound. 
3. A delivery system for cytokines with biodegrad 
able multi-phase microspheres, said microspheres com 
prising a cytokine contained within a fixed oil, and an 
essentially water insoluble, biodegradable polymeric 
matrix of polylactic acid or polylactic glycolic acid, 
wherein the polymeric matrix surrounds the fixed oil 
and wherein the fixed oil contains the cytokine. 
4. A delivery system for tumor necrosis factor with 
biodegradable multi-phase microspheres said micro 
spheres comprising a lyophilized microemulsion of an 
aqueous solution of tumor necrosis factor in a fixed oil, 
and an essentially water insoluble, biodegradable poly 
meric matrix of polylactic acid or polylactic glycolic 
acid, wherein the polymeric matrix surrounds said mi 
croemulsion of tumor necrosis factor and fixed oil. 
5. The delivery system of claim 1 wherein the molec 




6. The delivery system of claim 1, 2, 3 or 4 wherein 
the multi-phase microsphere is about 150 in size. 
7. The delivery system of claim 1, 2, 3 or 4 wherein 
the multi-phase microsphere is about between 50p to 
100u in size. 
8. The delivery system of claim 1 wherein the molec 
ular compound is water soluble and pharmacologically 
active. 
9. The delivery system of claim 8 wherein the molec 
ular compound is prepared as an aqueous solution to 
gether in a fixed oil to provide a microemulsion. 
10. The delivery system of claim 1 wherein the mo 
lecular compound is an enzyme. 
11. The delivery system of claim 1 wherein the mo 
lecular compound is selected from the group consisting 
of interferon, macrophage activation factor, interleukin, 
colony stimulating factor, tumor degenerating factor, 
epidermal growth factor, erythropoietin, tissue plasmin 
ogen activator, insulin, urokinase, luteinizing hormone 
releasing hormone, superoxide dismutase, or an anti 
body or an enzyme. 
12. The delivery system of claim 1 wherein the mo 
lecular compound is chlorpheniramine maleate, diphen 
hydramine hydrochloride, procainamide hydrochlo 
ride, promazine hydrochloride, or brilliant blue. 
13. The delivery system of claim 1, 2, 3 or 4 wherein 
the multi-phase microspheres are comprised of a biode 
gradable polymer of lactic acid or glycolic acid. 
14. The delivery system of claim 1, 2, 3 or 4 wherein 
the microspheres are comprised of a polymer poly (d.l)- 
lactic, poly (I)-lactic acid, or copolymers of lactic and 
glycolic acid. 
15. The delivery system of claim 1, 2, 3 or 4 wherein 
the fixed oil is safflower, soybean, cottonseed, peanut, 
sesame or cod liver oil. 
16. The delivery system of claim 1 wherein the mo 
lecular compound is tumor necrosis factor. 
17. The delivery system of claim 4 or 6 wherein the 
microemulsion consists of lyophilized tumor necrosis 
factor in a fixed oil and the polymeric matrix is poly-lac 
tic acid (PLGA). 
18. The delivery system of claim 17 wherein the fixed 
oil is soybean oil and includes aluminum monostearate. 
19. A method for providing sustained release of a 
protein, peptide, or drug in an animal comprising: 
preparing a formulation of microspheres, said micro 
spheres containing the protein, peptide, or drug in 
a fixed oil, and a biodegradable essentially water 
insoluble polymeric matrix of polylactic acid or 
polylactic glycolic acid; and 
administering an amount of the formulation effective 
to provide sustained release of the protein, peptide, 
or drug in the animal for a prescribed period of 
time, wherein the polymeric matrix surrounds the 
fixed oil and the fixed oil contains the protein, 
peptide, or drug. 
20. The method of claim 19 wherein the water-solu 
ble molecular compound is a protein, a peptide, a chem 
ical, or a drug. 
21. The method of claim 19 wherein the molecular 
compound is a therapeutic agent. 
22. The method of claim 19 wherein the molecular 
compound is CPM, DPH, PMZ, TNF or PRC. 
23. The method of claim 19 wherein the formulation 
is administered parenterally. 
24. The method of claim 19 wherein the formulation 












25. The method of claim 19 wherein the protein, 
peptide, or drug is water-soluble and is prepared as an 
aqueous solution together in a fixed oil to provide a 
microemulsion and wherein the polymeric matrix sur 
rounds the microemulsion. 
26. The method of claim 19 wherein sustained release 
of the molecular compound is provided for up to 1 year. 
27. The method of claim 19 wherein sustained release 
of the molecular compound is provided for about 3 
months. 
28. The method of claim 19 wherein the molecular 
compound is water-soluble. 
29. A method for preparing multi-phase microspheres 
containing a protein, peptide, or dug comprising: 
mixing an aqueous solution of the protein, peptide, or 
drug with a fixed oil to form a W/O microemul 
Sion; 
mixing polylactic acid or polylactic glycolic acid and 
a polymer solvent together to form a polymer solu 
tion; 
dispersing the microemulsion into the polymer solu 
tion to form a W/O/"O' emulsion; 
mixing the W/O/"O" emulsion together in a disper 
sion oil which is incompatible with the polymer 
solvent to form a multiple emulsion; 
agitating and removing the solvent from the multiple 
emulsion to form hardened microspheres; and 
washing and drying the hardened microspheres to 
form multi-phase microspheres containing the 
water-soluble protein, peptide, or drug. 
30. The method of claim 29 wherein the fixed oil of 
the microemulsion is soybean, cottonseed, peanut, ses 
ame cod liver oil or safflower oil. 
31. The method of claim 29 wherein the polymer 
solvent is acetonitrile or methylene chloride. 
32. The method of claim 29 wherein the polymer is 
PLA or PLGA. 
33. The method of claim 29 wherein the polymer 
solution comprises PLA and acetonitrile. 
34. The method of claim 29 wherein the molecular 
compound is a protein, a peptide, a chemical or a drug. 
35. The method of claim 29 wherein the microspheres 
are about 150 in size. 
36. The method of claim 29 wherein the microspheres 
are between about 50p and about 100u in size. 
37. The method of claim 29 wherein the molecular 
compound is water soluble and is selected from the 
group consisting of CPM, DPH, brilliant blue, PMZ, 
and PRC. 
38. The method of claim 29 wherein the microemul 
sion comprises about 1% w/w Tween 80 of the micro 
emulsion. 
39. The method of claim 29 wherein the microemul 
sion comprises about 2% aluminum monostearate and 
about 5% W/W Span 80 of the microemulsion. 
40. The method of claim 29 wherein the multiple 
emulsion comprises about 0.25% to 2% w/w Span 80. 













colony stimulating factor; 
tumor degenerating factor; 
epidermal growth factor; 
erythroprotein; 
tissue plasminogen activator; 
urokinase; 
Superoxide dismutase or 
P-450. 
42. The method of claim 2 wherein the ratio of micro 
emulsion to polymer is between about 0.25 to 1.0 grams 
to 1 by weight. 
43. The method of claim 29 wherein the molecular 
compound is unstable in water, and wherein the micro 
emulsion is lyophilized prior to dispersing the micro 
emulsion into the polymer solution to form a 
W/O/'W' emulsion. 
44. The method of claim 43 wherein the molecular 
compound is TNF. 
45. A method for preparing microspheres containing 
a water-soluble drug comprising: 
preparing a first mixture of a water-soluble drug in 
water, gelatin and Tween 80 to form an aqueous 
phase; 
preparing a second mixture of an amount of alumi 
num stearate and a volume of a fixed oil to produce 
a 2% w/w aluminum stearate and about 5% w/w 
Span 80 oil phase; 
combining the first mixture with the second mixture 
to form a coarse W/O emulsion; 
processing the coarse W/O emulsion into a fine W/O 
microemulsion; 
preparing a third mixture of polylactic acid or poly 
lactic glycolic acid and a solvent; 
combining a quantity of the fine W/O microemulsion 
with the third mixture to form a W/O/"O' emul 
sion; 
preparing a fourth mixture of an amount of Span 80 
and an oil incompatible with the polymer solvent; 
pouring the W/O/"O" emulsion into the fourth mix 
ture to form a multiple emulsion; 
agitating and evaporating the polymer solvent from 
the multiple emulsion to form hardened micro 
spheres; 
separating the hardened microspheres from the mix 
ture; and 
washing and drying the hardened microspheres to 
form multi-phase microspheres containing a water 
soluble drug. 
46. The method of claim 45 wherein the third mixture 
comprises less than 35% w/w of the polymer. 
47. The method of claim 45 wherein the third mixture 
comprises about 33% w/w of a PLA biodegradable 
polymer in an acetonitrile solvent. 
48. The method of claim 45 wherein the third mixture 
comprises about 31% w/w of a PLGA biodegradable 
polymer in an acetonitrile solvent. 
49. The method of claim 45 wherein the water-solu 
ble molecular compound is CPM, DPH, PMZ, or PRC. 
50. The method of claim 45 wherein the quantity of 
the fine W/O emulsion is between about 0.25 to 1.0 g by 












51. The method of claim 45 wherein the fourth mix 
ture includes between about 0.25% to about 2% w/w 
Span 80. 
52. The method of claim 45 wherein the fourth mix 
ture includes about 0.254 to 0.5% w/w Span 80. 
53. The method of claim 45 wherein the fourth mix 
ture includes about 0.254 w/w Span 80. 
54. A multi-phase microsphere for the delivery of a 
peptide, protein, or drug comprising a biodegradable 
essentially water insoluble polymeric matrix of polylac 
tic acid or polylactic glycolic acid surrounding a pro 
tein, peptide, or drug contained within a fixed oil, said 
microsphere prepared by a process of: 
preparing a first mixture of a water-soluble protein, 
peptide, or dug in water, gelatin and Tween 80 to 
form an aqueous base; 
preparing a second mixture of an amount of alumi 
num stearate and a volume of a fixed oil to produce 
a 2% w/w aluminum stearate and about 5% w/w 
span 80 oil phase; 
combining the first mixture with the second mixture 
to form a coarse W/O emulsion; 
processing the coarse W/O emulsion into a fine W/O 
micro emulsion; 
preparing a third mixture of a biodegradable essen 
tially water-insoluble polymer polylactic acid of 
polylactic glycolic acid and a solvent; 
combining a quantity of the fine W/O micro emulsion 
with the third mixture to form a W/O/"O' emul 
Slon; 
preparing a fourth mixture of an amount of span 80 
and an oil incompatible with the polymer solvent; 
pouring the W/O/"O" emulsion into the fourth mix 
ture to form a multiple emulsion; 
evaporating the solvent from the multiple emulsion to 
form hardened microspheres; 
separating the hardened microspheres from the mix 
ture; and 
washing and drying the hardened microspheres to 
form multi-phase microspheres containing a water 
soluble protein, peptide, or drug. 
55. The microsphere of claim 54 wherein the fixed oil 
is safflower, soybean, cottonseed, peanut, sesame or cod 
liver oil. 
56. The microsphere of claim 54 wherein the protein 
is tumor necrosis factor. 
57. The microsphere of claim 54 wherein the biode 
gradable polymer is poly(d,l-lactic acid) or poly(d,l-lac 
tic) co-glycolic lactic acid. 
58. A biodegradable polymeric microsphere compris 
ing an essentially water insoluble poly (d.l-lactic acid) 
or poly (d,l-lactic) co-glycolic acid polymeric matrix 
surrounding a protein-containing fixed oil droplet. 
59. The biodegradable polymeric microsphere of 
claim 58 wherein the polymeric matrix is poly(d,l-lactic 
acid). 
60. The biodegradable polymeric microsphere of 
claim 58 wherein the fixed oil is safflower, soybean, 
cottonseed, peanut, sesame or cod liver oil. 
61. The biodegradable polymeric microsphere of 
claim 58 wherein the protein is tumor necrosis factor of 
interleukin-1. 
62. The biodegradable polymeric microsphere of 
claim 58 wherein the microsphere has a diameter of 
between 50p and 200u. 
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